The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

#	Paper	IF	Citations
1780	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. **2014**, 148, 511-23		23
1779	Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. **2015**, 65, 644-51		29
1778	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. **2015**, 1,		78
1777	CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. **2015**, 17, 839-48		46
1776	Prognosefaktoren gynäkologischer Malignome. **2015**, 48, 858-864		
1775	Gene-expression signature functional annotation of breast cancer tumours in function of age. **2015**, 8, 80		2
1774	The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. **2015**, 13, 168		26
1773	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. **2015**, 17, 124		151
1772	An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. **2015**, 17, 131		50
1771	Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. **2015**, 22, 306-13		11
1770	A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. **2015**, 7, 389-97		7
1769	High definition infrared spectroscopic imaging for lymph node histopathology. **2015**, 10, e0127238		38
1768	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. **2015**, 6, 13506-19		87
1767	Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. **2015**, 9, 1120-8		22
1766	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. *Annals of Oncology*, **2015**, 26, 1698-704	10.3	183
1765	A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery. **2015**, 14, 2807-18		28
1764	Adoptive T-cell therapy for cancer: The era of engineered T cells. **2015**, 45, 2457-69		60

1745   Global Transcriptional Changes Following Statin Treatment in Breast Cancer. **2015**, 21, 3402-11   39

1744   Therapeutic Impact of Immune Responses in Cancer. **2015**, 221-245

1743   Immunotherapeutic options on the horizon in breast cancer treatment. **2015**, 156, 90-101   15

1742   Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. *Annals of Oncology*, **2015**, 26, 2351   10.3   15

1741   Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. **2015**, 1, 448-54   359

1740   Relevance of tumor-infiltrating lymphocytes in breast cancer. **2015**, 13, 202   131

1739   Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. **2015**, 154, 239-49   22

1738   High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. **2015**, 467, 701-709   22

1737   Immunity and HER2-positive disease: never stop questioning. *Annals of Oncology*, **2015**, 26, 2361-2   10.3   2

1736   Natural and therapy-induced immunosurveillance in breast cancer. **2015**, 21, 1128-38   196

1735   Facteurs pronostiques et prédictifs de réponse aux immunothérapies (TILs, TAM). **2015**, 17, 397-401

1734   Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development. **2015**, 7, 151-160

1733   Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). **2015**, 4, e985930   47

1732   Breast cancer and immunology: biomarker and therapeutic developments. **2015**, 15, 1215-22   9

1731   Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. **2015**, 7, 315ra188   177

1730   Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. **2016**, 7, 32113-28   81

1729   The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma. **2016**, 9, 7177-7185   43

1728   Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. **2016**, 19, 261-267   14

| 1709 | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. **2016**, 16, 472-7 | 13 |

| 1708 | Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer. **2016**, 69, 552-5 | 4 |

| 1707 | Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes. **2016**, 69, 890-8 | 14 |

| 1706 | Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. **2016**, 4, 76 | 122 |

| 1705 | Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups. **2016**, 18, 74 | 41 |

| 1704 | An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. **2016**, 18, 121 | 73 |

| 1703 | CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan. **2016**, 1, | 4 |

| 1702 | Immune DNA signature of T-cell infiltration in breast tumor exomes. **2016**, 6, 30064 | 24 |

| 1701 | Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. **2016**, 107, 1730-1735 | 75 |

| 1700 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. **2016**, 13, 674-690 | 1246 |

| 1699 | Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. **2016**, 22, 5747-5754 | 116 |

| 1698 | The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. **2016**, 46, 9-19 | 60 |

| 1697 | Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. **2016**, 29, 476-88 | 67 |

| 1696 | Highlights of the 2015 San Antonio Breast Cancer Symposium. **2016**, 3, 110-113 | |

| 1695 | The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. **2016**, 114, 1145-51 | 22 |

| 1694 | Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. **2016**, 4, 600-10 | 61 |

| 1693 | Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. **2016**, 11, 96-100 | 25 |

| 1692 | MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. **2016**, 156, 597-606 | 16 |

1691 The genomic landscape of breast cancer and its interaction with host immunity. **2016**, 29, 241-50   130

1690 Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. **2016**, 40, 151-162   16

1689 Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. **2016**, 50, 205-207   41

1688 Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. *Annals of Oncology*, **2016**, 27, 1867-73   10.3   68

1687 An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes. **2016**, 146, 137-44   18

1686 [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. **2016**, 37, 557-567   31

1685 CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in´situ. **2016**, 5, 1607-18   22

1684 A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. **2016**, 22, 5729-5737   109

1683 Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. **2016**, 4, 835-844   95

1682 Correlation Between MRI and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer. **2016**, 207, 1146-1151   23

1681 Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. **2016**, 8, 360-74   33

1680 Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. **2016**, 2, 16036   89

1679 Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. **2016**, 18, 78   51

1678 Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. **2016**, 103, 845-54   68

1677 Biology and Management of Patients With Triple-Negative Breast Cancer. **2016**, 21, 1050-62   131

1676 Immunothḗapie et cancer du sein. **2016**, 18, 551-558   2

1675 In-silico insights on the prognostic potential of immune cell infiltration patterns in the breast lobular epithelium. **2016**, 6, 33322   17

1674 Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. **2016**, 5, e1248015   26

1673 Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. **2016**, 6, 36231 — 17

1672 Clinical significance of tumor-infiltrating lymphocytes in breast cancer. **2016**, 4, 59 — 279

1671 Network-Based Enriched Gene Subnetwork Identification: A Game-Theoretic Approach. **2016**, 7, 1-14 — 5

1670 Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. **2016**, 10, 31-9 — 88

1669 Conservation of immune gene signatures in solid tumors and prognostic implications. **2016**, 16, 911 — 50

1668 Immunological Mechanisms in Breast Cancer - from Bench to Bedside. **2016**, 11, 93-4

1667 p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?. **2016**, 55, 196-201 — 3

1666 Immunotherapy in Breast Cancer. **2016**, 39, 335-45 — 11

1665 Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. **2016**, 14, 112 — 27

1664 Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. **2016**, 35, 62 — 19

1663 PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. **2016**, 55, 182-9 — 44

1662 Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. **2016**, 158, 1-9 — 35

1661 Checkpoint Inhibitors and Their Application in Breast Cancer. **2016**, 11, 108-15 — 33

1660 Identification of stromal ColXⓐ and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. **2016**, 16, 274 — 26

1659 Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. **2016**, 18, 50 — 42

1658 Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. **2016**, 5, e1153208 — 30

1657 Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. **2016**, 18, 21 — 43

1656 No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014. **2016**, 114, 17-21 — 8

1655   Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. **2016**, 21, 548-56   23

1654   The immune microenvironment of breast ductal carcinoma in situ. **2016**, 29, 249-58   98

1653   Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. **2016**, 76, 264-74   17

1652   Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. **2016**, 2, 46-54   527

1651   Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. **2016**, 5, e1069936   38

1650   Clinical relevance of host immunity in breast cancer: from TILs to the clinic. **2016**, 13, 228-41   429

1649   PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. **2016**, 47, 52-63   214

1648   Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. **2016**, 21, 283-91   35

1647   Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. **2016**, 12, 1413-28   21

1646   Emerging therapeutic targets in metastatic progression: A focus on breast cancer. **2016**, 161, 79-96   37

1645   Translating neoadjuvant therapy into survival benefits: one size does not fit all. **2016**, 13, 566-79   28

1644   Identification of immune cell infiltration in hematoxylin-eosin stained breast cancer samples: texture-based classification of tissue morphologies. **2016**,   3

1643   New Strategies in Breast Cancer: Immunotherapy. **2016**, 22, 2105-10   90

1642   Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer. **2016**, 8, 1-13   5

1641   Biomarkers of residual disease after neoadjuvant therapy for breast cancer. **2016**, 13, 487-503   36

1640   Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. **2016**, 34, 1223-30   194

1639   Breast cancer stem cells phenotype and plasma cell-predominant breast cancer independently indicate poor survival. **2016**, 212, 294-301   11

1638   The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. **2016**, 11, 789-800   229

1637	Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. **2016**, 23, 2242-8		53
1636	Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. **2016**, 156, 237-47		70
1635	Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. *Annals of Oncology*, **2016**, 27, 494-501	10.3	89
1634	Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. *Annals of Oncology*, **2016**, 27, 225-32	10.3	100
1633	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. *Annals of Oncology*, **2016**, 27, 249-56	10.3	96
1632	Annals of oncology in 2015: the year in review. *Annals of Oncology*, **2016**, 27, 8-9	10.3	
1631	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. **2016**, 22, 704-13		138
1630	Characterization of human breast cancer tissues by infrared imaging. **2016**, 141, 606-19		45
1629	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. **2016**, 22, 1499-509		311
1628	TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. **2016**, 5, e1073882		28
1627	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. **2016**, 37, 4135-42		28
1626	Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. **2016**, 69, 422-30		91
1625	Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. **2016**, 16, 51-8		57
1624	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. **2016**, 2, 56-64		141
1623	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. **2017**, 24, 3-15		107
1622	Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. **2017**, 17, 61-69.e3		46
1621	Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. **2017**, 108, 81-90		35
1620	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. **2017**, 110, 106-116		29

1601	Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. **2017**, 66, 1131-1142	4
1600	Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIᴂn the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. **2017**, 62, 246-255	6
1599	Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ. **2017**, 64, 145-155	1
1598	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. **2017**, 77, 3540-3550	213
1597	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. **2017**, 57, 8-15	49
1596	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. **2017**, 8, 15081	459
1595	Is tumor cellularity in primary invasive breast carcinoma of prognostic significance?. **2017**, 470, 611-617	1
1594	Image analysis of immune cell patterns in the human mammary gland during the menstrual cycle refines lymphocytic lobulitis. **2017**, 164, 305-315	1
1593	Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features. **2017**, 23, 5210-5217	41
1592	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. **2017**, 30, 1204-1212	50
1591	High expression of CD8 predicts favorable prognosis in patients with lung adenocarcinoma: A cohort study. **2017**, 96, e6472	27
1590	Advancing Immunotherapy in Metastatic Breast Cancer. **2017**, 18, 35	12
1589	Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. *Annals of Oncology*, **2017**, 28, 2233-2240	10.3 51
1588	Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer. **2017**, 24, 3780-3787	14
1587	Immunotherapy for Breast Cancer: What Are We Missing?. **2017**, 23, 2640-2646	112
1586	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. **2017**, 9,	167
1585	Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. **2017**, 165, 293-300	23
1584	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. **2017**, 34, 83-88	17

1583   Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma. **2017**, 7, 44823   32

1582   Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. **2017**, 71, 258-268   36

1581   Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. **2017**, 70, 860-867   30

1580   Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. **2017**, 39, 1010428317695023   41

1579   Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. **2017**, 18, 339-346   13

1578   New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. **2017**, 141, 490-498   37

1577   Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. **2017**, 163, 295-302   13

1576   Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. **2017**, 82, 219-227   53

1575   Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. **2017**, 17, 735-746   36

1574   Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies Inactivation Impairing Immunorecognition. **2017**, 23, 3203-3213   45

1573   Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. **2017**, 90, 24-37   27

1572   Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma. **2017**, 66, 343-354   33

1571   Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. **2017**, 18, 52-62   164

1570   PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. **2017**, 140, 1384-1395   26

1569   Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. **2017**, 23, 3203-3213   45

1568   PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. **2017**, 162, 19-30   70

1567   Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. **2017**, 49, 141-155   68

1566   Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. **2017**, 6, e1257452   106

1565	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. *Annals of Oncology*, **2017**, 28, 321-328	10.3	55
1564	Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital. **2017**, 10, 699-705		2
1563	The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. **2017**, 69, 110-117		49
1562	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. **2017**, 1868, 527-537		29
1561	The Antibody Repertoire of Colorectal Cancer. **2017**, 16, 2111-2124		3
1560	CD21CD27 proinflammatory B cells are enriched in breast cancer patients and promote antitumor T cell responses. **2017**, 361, 149-154		2
1559	LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. *Annals of Oncology*, **2017**, 28, 2977-2984	10.3	93
1558	Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. **2017**, 15, 1722-1732		70
1557	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. **2017**, 5, 871-884		41
1556	Immunology of Solid Tumors Beyond Tumor-Infiltrating Lymphocytes: The Role of Tertiary Lymphoid Structures. **2017**, 259-280		
1555	Tumour infiltrating lymphocytes are predictors of lymph node metastasis in early gastric cancers. **2017**, 49, 589-595		14
1554	Gene expression profiling of calcifications in breast cancer. **2017**, 7, 11427		13
1553	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. **2017**, 7, 11671		43
1552	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). **2017**, 85, 133-145		54
1551	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. **2017**, 46, 1180-1187		31
1550	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. **2017**, 8, 606		60
1549	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. **2017**, 50, 185-194		21
1548	Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. **2017**, 32,		13

1547 Therapeutic Implications of Angiogenesis in Cancer. **2017**, 171-216

1546 The Challenge for Development of Valuable Immuno-oncology Biomarkers. **2017**, 23, 4970-4979   54

1545 Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. **2017**, 22, 1316-1324   41

1544 PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. **2017**, 30, 1551-1560   30

1543 Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. **2017**, 148, 108-118   9

1542 Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. **2017**, 35, 142-150   66

1541 CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. **2017**, 66, 1449-1461   38

1540 Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. **2017**, 3, e172085   23

1539 HER2-positive breast cancer is lost in translation: time for patient-centered research. **2017**, 14, 669-681   49

1538 Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. **2017**, 19, 64   71

1537 Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. **2017**, 24, 311-335   299

1536 Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. **2017**, 24, 235-251   293

1535 Targeting immune checkpoints in breast cancer: an update of early results. **2017**, 2, e000255   79

1534 PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma. **2017**, 12, 72   17

1533 T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. **2017**, 114, E10409-E10417   40

1532 A high ratio of IL-12R⊠-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer. **2017**, 74, 148-156   8

1531 Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. **2017**, 87, 164-171   7

1530 Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. **2017**, 70, 129-138   10

1529	Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer. **2017**, 24, 4042-4050		15
1528	HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. **2017**, 117, 451-460		188
1527	PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study. **2017**, 35, 69-77		18
1526	Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. **2017**, 19, 71		37
1525	Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. **2017**, 17, 375		81
1524	Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. **2017**, 5, 39		40
1523	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. **2017**, 5, 44		139
1522	Heterogeneity of CD8 tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on´patient prognostic assessments and comparison of quantification by different sampling strategies. **2017**, 66, 33-43		20
1521	Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers. **2017**, 31, 34-39		5
1520	Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). *Annals of Oncology*, **2017**, 28, 651-657	10.3	85
1519	Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. **2017**, 161, 41-50		11
1518	Pathology and Molecular Pathology of Breast Cancer. **2017**, 173-231		0
1517	Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. **2017**, 18, 220-233.e8		60
1516	CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. **2017**, 470, 81-90		4
1515	Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma. **2017**, 10, 10-16		40
1514	Antitumor immunity and advances in cancer immunotherapy. **2017**, 24, 1-2		6
1513	Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. **2017**, 14, 6421-6432		23
1512	Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. **2017**, 17, 888		28

1511	DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. **2017**, 127, 3090-3102	63
1510	Immune-stroma-histological (ISH)-risk score identifies low-risk group within LN-positive breast cancers. *Annals of Oncology*, **2017**, 28, vii27-vii28	10.3
1509	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. **2017**, 1,	7
1508	Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. **2017**, 18,	10
1507	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. **2017**, 8, 1412	54
1506	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. **2017**, 7, 156	64
1505	Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. **2017**, 2017, 7849108	15
1504	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. **2017**, 2017, 1750925	31
1503	Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. **2017**, 12, e0170634	55
1502	Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. **2017**, 12, e0182786	40
1501	Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. **2017**, 17, 657	29
1500	Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate. **2017**, 12, 69	15
1499	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. **2017**, 19, 91	59
1498	Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. **2017**, 45, 19	6
1497	Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. **2017**, 11, 759	14
1496	Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. **2017**, 8, 124-130	16
1495	Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. **2017**, 8, 113345-113359	42
1494	The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. **2017**, 8, 38850-38862	23

1493   Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. **2017**, 8, 83986-83994   45

1492   Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. **2018**, 31, 1012-1025   19

1491   Immune Infiltration in Invasive Lobular Breast Cancer. **2018**, 110, 768-776   55

1490   Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer. **2018**, 110, 696-698   4

1489   Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. **2018**, 18, 410-417   15

1488   TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. **2018**, 13, 8-14   19

1487   NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings. **2018**, 11, 374-390   14

1486   Inflammatory breast cancer: The pathologists' perspective. **2018**, 44, 1128-1134   12

1485   Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. **2018**, 144, 1219-1226   37

1484   Atezolizumab for the treatment of breast cancer. **2018**, 18, 595-603   12

1483   Towards predictive biomarkers for immunotherapy response in breast cancer patients. **2018**, 7, BMT05   4

1482   Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. **2018**, 16, 86   25

1481   Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. **2018**, 19, 22   41

1480   Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. **2018**, 23, 181-193.e7   366

1479   PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. **2018**, 73, 386-396   14

1478   [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. **2018**, 105, 263-274   10

1477   Immuno-oncology-101: overview of major concepts and translational perspectives. **2018**, 52, 1-11   30

1476   Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. **2018**, 143, 419-429   5

1475 Immune gene expression and response to chemotherapy in advanced breast cancer. **2018**, 118, 480-488 — 20

1474 Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A large-scale cohort study. **2018**, 142, 2558-2566 — 43

1473 Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. **2018**, 25, 937-946 — 26

1472 Pathologic Evaluation of Triple-Negative Breast Cancer. **2018**, 1-22 — 2

1471 Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. **2018**, 124, 2086-2103 — 94

1470 Checkpoint Blockade. **2018**, 37-53

1469 T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. **2018**, 135, 581-599 — 38

1468 Annals of Oncology: factors for making a real impact. *Annals of Oncology*, **2018**, 29, 28-29 — 10.3 1

1467 Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. **2018**, 20, 815-826 — 43

1466 Network science in clinical trials: A patient-centered approach. **2018**, 52, 135-150 — 6

1465 LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival. **2018**, 19, 249-259.e2 — 31

1464 Molecular Oncology of Breast Cancer. **2018**, 282-307.e5 — 5

1463 Therapeutic Strategies for Breast Cancer. **2018**, 315-330.e7 — 3

1462 Immunologic Approaches to Breast Cancer Therapy. **2018**, 924-933.e4

1461 Tumor-infiltrating lymphocytes are associated with -catenin overexpression in breast cancer. **2018**, 21, 639-650 — 6

1460 Primary Systemic Therapy for Breast Cancer. **2018**, 453-462

1459 Challenges of Oncoimmunology for Ovarian and Breast Cancers. **2018**, 607-619

1458 The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC). **2018**, 19, 296-305 — 25

| 1457 | TIM-3 Regulates CD103 Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. **2018**, 33, 60-74.e6 | 141 |

| 1456 | Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. **2018**, 4, 39-54 | 14 |

| 1455 | Analyzing the Immunological Landscape of a Tumor Heterogeneity of Immune Infiltrates in Breast Cancer as a New Prognostic Indicator. **2018**, 110, 129-130 | 1 |

| 1454 | Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer. **2018**, 14, 835-847 | 9 |

| 1453 | Immunotherapy for Other Malignancies. **2018**, 125-142 | |

| 1452 | The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. **2018**, 47, 683-690 | 20 |

| 1451 | Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. **2018**, 18, 129 | 31 |

| 1450 | A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. **2018**, 18, 371 | 14 |

| 1449 | Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. **2018**, 16, 54 | 9 |

| 1448 | Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. **2018**, 16, 87 | 27 |

| 1447 | Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. **2018**, 9, 606-612 | 3 |

| 1446 | Breast cancer intratumour heterogeneity: current status and clinical implications. **2018**, 73, 717-731 | 21 |

| 1445 | N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome. **2018**, 12, 972-990 | 12 |

| 1444 | Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma. **2018**, 77, 88-97 | 10 |

| 1443 | [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. **2018**, 51, 97-109 | 4 |

| 1442 | Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. **2018**, 17, 1324-1331 | 45 |

| 1441 | Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. **2018**, 18, e1123-e1132 | 18 |

| 1440 | Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. **2018**, 24, 2851-2858 | 38 |

1439	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. **2018**, 31, 1226-1236		40
1438	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. **2018**, 24, 2804-2811		167
1437	Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment. **2018**, 17, 1533033818764499		15
1436	Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. **2018**, 168, 135-145		18
1435	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. **2018**, 170, 293-302		10
1434	An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. **2018**, 26, 611-619		16
1433	Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy. **2018**, 26, 523-532		20
1432	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). **2018**, 25, 34-42		60
1431	Tumor infiltrating lymphocytes in early breast cancer. **2018**, 37, 207-214		64
1430	Rationale for immunological approaches to breast cancer therapy. **2018**, 37, 187-195		14
1429	Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: Usefulness of breast MRI computer-aided detection and diagnosis. **2018**, 47, 760-766		17
1428	Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. **2018**, 67, 161-174		18
1427	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. *Annals of Oncology*, **2018**, 29, 170-177	10.3	45
1426	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. *Annals of Oncology*, **2018**, 29, 162-169	10.3	26
1425	Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. **2018**, 24, 407-419		124
1424	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. **2018**, 52, 16-25		181
1423	Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. **2018**, 31, 288-298		31
1422	Invasive breast carcinomas with ATM gene variants of uncertain significance share distinct histopathologic features. **2018**, 24, 291-297		1

| 1421 | Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. **2018**, 72, 449-459 | 54 |

| 1420 | The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system. **2018**, 53, 606-617 | 23 |

| 1419 | Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. **2018**, 167, 39-47 | 17 |

| 1418 | Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. **2018**, 18, e373-e379 | 6 |

| 1417 | Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. **2018**, 167, 89-99 | 48 |

| 1416 | Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. **2018**, 57, 74-82 | 64 |

| 1415 | Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. **2018**, 57, 90-94 | 19 |

| 1414 | Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer. **2018**, 25, 268-274 | 9 |

| 1413 | Implications of the tumor immune microenvironment for staging and therapeutics. **2018**, 31, 214-234 | 182 |

| 1412 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. **2018**, 19, 40-50 | 730 |

| 1411 | Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. **2018**, 19, 3-5 | 17 |

| 1410 | Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. **2018**, 143, 8-15 | 16 |

| 1409 | Breast cancer genomics and immuno-oncological markers to guide immune therapies. **2018**, 52, 178-188 | 68 |

| 1408 | Single-cell heterogeneity in ductal carcinoma in situ of breast. **2018**, 31, 406-417 | 31 |

| 1407 | Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. **2018**, 110, | 83 |

| 1406 | Aligning digital CD8 scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. **2018**, 72, 270-284 | 12 |

| 1405 | Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. **2018**, 32, 151-158 | 27 |

| 1404 | Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer. **2018**, 9, 15180-15197 | 9 |

1403	A model for anticancer surveillance was pharmacologically developed to evaluate vitality principle in breast cancer rats. **2018**, 38, 823-833	
1402	Identification of fatal outcome in a childhood nasopharyngeal carcinoma patient by protein expression profiling. **2018**, 53, 1721-1731	4
1401	Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. **2019**, 17, 2177-2186	10
1400	Amyloid Precursor Protein Is Associated with Aggressive Behavior in Nonluminal Breast Cancers. **2018**, 23, 1273-1281	11
1399	Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes. **2018**,	7
1398	[TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes]. **2018**, 39, 236-240	2
1397	Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy. **2018**, 13, 757-767	9
1396	Possibility of avoiding axillary lymph node dissection by immune microenvironment monitoring in preoperative chemotherapy for breast cancer. **2018**, 16, 318	4
1395	Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. **2018**, 13, e0207224	25
1394	Fine-tuning chemotherapy in the era of dual HER2 targeting. **2018**, 19, 1551-1554	1
1393	Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer. **2018**, 10, 262-273	1
1392	T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer. **2018**, 21, 406-414	20
1391	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. **2018**, 2018, 2937012	25
1390	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. **2018**, 4, 40	17
1389	HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy. **2018**, 9, 2605	26
1388	SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art. **2018**, 6, 138	16
1387	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced by Tumor-Infiltrating B Cells in Breast Cancer. **2018**, 9, 2660	38
1386	B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration. **2018**, 40, 1010428318815032	8

| 1385 | Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. **2018**, 8, 609 | 11 |

| 1384 | Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. **2018**, 7, 5066-5082 | 6 |

| 1383 | Distribution and prognostic value of tumor-infiltrating T cells in breast cancer. **2018**, 18, 4247-4258 | 14 |

| 1382 | Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment. **2018**, 119, 572-579 | 9 |

| 1381 | Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. **2018**, 6, 98 | 27 |

| 1380 | Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. **2018**, 3, e000305 | 19 |

| 1379 | Heterogeneity and Plasticity of Immune Inflammatory Responses in the Tumor Microenvironment: Their Role in the Antitumor Effect and Tumor Aggressiveness. **2018**, 8, 431-448 | 5 |

| 1378 | Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. **2018**, 9, 2582 | 33 |

| 1377 | Prognostic significance of interferon regulating factor 4 in esophageal squamous cell carcinoma. **2018**, 506, 685-691 | 2 |

| 1376 | An isoform of AIF1 involved in breast cancer. **2018**, 18, 167 | 5 |

| 1375 | The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. **2018**, 119, 1383-1391 | 23 |

| 1374 | High expression of E-cadherin and Ki-67 associated with functional/dysfunctional phenotypes of tumor-infiltrating lymphocytes among Chinese patients with operable breast cancer. **2018**, 46, 5219-5227 | 4 |

| 1373 | Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. **2018**, 10, 4333-4347 | 22 |

| 1372 | Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. **2018**, 97, e11769 | 54 |

| 1371 | Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. **2018**, 151, 414-421 | 23 |

| 1370 | Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). **2018**, 11, 124 | 12 |

| 1369 | [Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis]. **2018**, 39, 520-531 | 3 |

| 1368 | An assessment of prognostic immunity markers in breast cancer. **2018**, 4, 35 | 22 |

1367 | Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. **2018**, 10, 81 | 46

1366 | TIM-3 expression in breast cancer. **2018**, 7, e1502128 | 34

1365 | Plug-and-Play Nanorization of Coarse Black Phosphorus for Targeted Chemo-photoimmunotherapy of Colorectal Cancer. **2018**, 12, 10061-10074 | 68

1364 | Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy. **2018**, 42, 61-67 | 5

1363 | Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. **2018**, 20, 101 | 25

1362 | A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. **2018**, 174, 1373-1387.e19 | 378

1361 | Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. **2018**, 20, 108 | 53

1360 | A contemporary review of male breast cancer: current evidence and unanswered questions. **2018**, 37, 599-614 | 32

1359 | Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer. **2018**, 103, 52-60 | 9

1358 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, -like status, tumor-infiltrating immune cells and survival. **2018**, 7, e1509820 | 51

1357 | Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. *Annals of Oncology*, **2018**, 29, 2175-2182 | 10.3 | 13

1356 | Immunological differences between primary and metastatic breast cancer. *Annals of Oncology*, **2018**, 29, 2232-2239 | 10.3 | 132

1355 | Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. **2018**, 13, 66 | 18

1354 | -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. **2018**, 21, 45-50 |

1353 | Immune characterization of breast cancer metastases: prognostic implications. **2018**, 20, 62 | 32

1352 | Checkpoint blockade in the treatment of breast cancer: current status and future directions. **2018**, 119, 4-11 | 55

1351 | Low neutrophil-lymphocyte ratio correlates with extended survival in patients with metastatic breast cancer who achieved clinically complete response following multidisciplinary therapy: A retrospective study. **2018**, 15, 6681-6687 | 9

1350 | Hot Spot and Whole-Tumor Enumeration of CD8 Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer. **2018**, 18, 451-458.e1 | 18

| 1349 | Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. **2018**, 171, 1-9 | 27 |

| 1348 | Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. **2018**, 79, 160-167 | 19 |

| 1347 | Molecular Biology of Breast Cancer. **2018**, 569-588 | 3 |

| 1346 | Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. **2018**, 52, 253-258 | 5 |

| 1345 | The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. **2018**, 171, 273-282 | 40 |

| 1344 | Elucidation of inhibitory effects on metastatic sentinel lymph nodes of breast cancer during One-Step Nucleic Acid Amplification. **2018**, 8, 7563 | 2 |

| 1343 | Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. **2018**, 73, 887-896 | 38 |

| 1342 | Basal-subtype bladder tumours show a 'hot' immunophenotype. **2018**, 73, 748-757 | 22 |

| 1341 | Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. **2018**, 151, 10-17 | 49 |

| 1340 | Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. **2018**, 7, e1466017 | 10 |

| 1339 | Tumor-infiltrating lymphocytes associate with outcome in nonendemic nasopharyngeal carcinoma: a multicenter study. **2018**, 81, 211-219 | 15 |

| 1338 | Tumor-Infiltrating Lymphocytes in Breast Cancer: Evaluating Interobserver Variability, Heterogeneity, and Fidelity of Scoring Core Biopsies. **2018**, 150, 441-450 | 12 |

| 1337 | Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality. **2018**, 10, 1365-1375 | 10 |

| 1336 | Viewing the Eph receptors with a focus on breast cancer heterogeneity. **2018**, 434, 160-171 | 16 |

| 1335 | Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. **2018**, 82, 104-112 | 26 |

| 1334 | High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. **2018**, 9, 1209 | 64 |

| 1333 | The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. **2018**, 8, 27 | 46 |

| 1332 | Androgen expression & clinicopathological features in male breast cancer. **2018**, 7, BMT07 | 1 |

1331 Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. **2018**, 52, 151-157 — 71

1330 Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer. **2018**, 25, 2852-2857 — 7

1329 A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. **2018**, 13, e0192744 — 23

1328 Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. **2018**, 171, 21-31 — 21

1327 Characterising the adipose-inflammatory microenvironment in male breast cancer. **2018**, 25, 773-781 — 5

1326 Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. **2018**, 18, 4 — 57

1325 Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC. **2018**, 18, 123 — 11

1324 Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. **2018**, 18, 320 — 11

1323 Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. **2018**, 16, 1 — 50

1322 Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy. **2018**, 8, 7485 — 14

1321 CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer. **2018**, 71, 1007-1014 — 9

1320 Human cancer evolution in the context of a human immune system in mice. **2018**, 12, 1797-1810 — 8

1319 Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. **2018**, 10, 91-103 — 43

1318 Functional Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. **2018**, 24, 6277-6287 — 31

1317 Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. *Annals of Oncology*, **2018**, 29, 2121-2128 — 10.3 — 41

1316 Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. **2018**, 188, 2378-2391 — 6

1315 Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. **2018**, 9, 33-41 — 12

1314 Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis. **2018**, 171, 295-302 — 17

1313	Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014. **2018**, 35, 77-79		12
1312	Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer. **2018**, 79, 188-198		27
1311	Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. **2018**, 4, 1237-1244		149
1310	Breast Cancer Immunotherapy: An Update. **2018**, 12, 1178223418774802		19
1309	Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer. **2018**, 80, 47-54		10
1308	Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. *Annals of Oncology*, **2018**, 29, 1755-1762	10.3	23
1307	Using deep convolutional neural networks to identify and classify tumor-associated stroma in diagnostic breast biopsies. **2018**, 31, 1502-1512		95
1306	CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis. **2018**, 13, e0190158		24
1305	Interleukin-13 receptor alpha 2 expression in tumor cells is associated with reduced disease-free survival in patients with luminal subtype invasive breast cancer. **2018**, 40, 1010428318783657		7
1304	New horizons in breast cancer: the promise of immunotherapy. **2019**, 21, 117-125		14
1303	Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. **2019**, 143, 330-337		237
1302	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. **2019**, 111, 69-77		40
1301	Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients. **2019**, 32,		5
1300	Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. **2019**, 32, 70-80		35
1299	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. **2019**, 14, e0219566		11
1298	Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer. **2019**, 178, 283-294		22
1297	An augmented reality microscope with real-time artificial intelligence integration for cancer diagnosis. **2019**, 25, 1453-1457		95
1296	LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. **2019**, 11,		44

1295   Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. **2019**, 10,   17

1294   Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group. **2019**, 11, 6815-6827   8

1293   Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. **2019**, 17, e909-e912   1

1292   Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients. **2019**, 121, 230-236   8

1291   Invasive Ductal Carcinoma (NOS) of the Breast. **2019**, 25-37

1290   Tumor-Infiltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infiltrating Lymphocytes in Invasive Breast Carcinoma. **2019**, 152, 656-665   6

1289   The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. **2019**, 10, 3108   36

1288   Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer. **2019**, 58, 1603-1611   2

1287   Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. **2019**, 8, e1629780   12

1286   Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. **2019**, 177, 603-610   12

1285   Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. **2019**, 118, 41-48   18

1284   Colorectal cancer, radiotherapy and gut microbiota. **2019**, 31, 212-222   11

1283   Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer. **2019**, 19, 615   5

1282   Wnt Signaling in Cancer Metabolism and Immunity. **2019**, 11,   54

1281   Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. **2019**, 11,   21

1280   The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer. **2019**, 177, 651-657   7

1279   Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. **2019**, 7, 265   37

1278   An innate-like Vδ1 T cell compartment in the human breast is associated with remission in triple-negative breast cancer. **2019**, 11,   56

1277   Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. **2019**, 25, 6731-6741   29

1276   [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]. **2019**, 39, 383-398   2

1275   Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1. **2019**, 11, 217-227   3

1274   Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer. **2019**, 42, 947-961   14

1273   Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. **2019**, 11, 1758835919882581   3

1272   Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. **2019**, 14, e0224726   17

1271   If we build it they will come: targeting the immune response to breast cancer. **2019**, 5, 37   76

1270   Stromal ColXa1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. **2019**, 19, 1036   2

1269   Breast cancer in Tanzanian, black American, and white American women: An assessment of prognostic and predictive features, including tumor infiltrating lymphocytes. **2019**, 14, e0224760   2

1268   Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. **2019**, 155, 483-488   3

1267   Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. **2019**, 9, 1040   22

1266   Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis. **2019**, 9, 985   7

1265   Breast Cancer Heterogeneity in Primary and Metastatic Disease. **2019**, 1152, 75-104   13

1264   Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. **2019**, 19, 857   46

1263   Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. **2019**, 10, 1939   26

1262   Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. **2019**, 9, 12594   2

1261   Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. **2019**, 3, 21   17

1260   Ductal carcinoma in situ of breast: update 2019. **2019**, 51, 563-569   16

1241	Budding, tumor-infiltrating lymphocytes, gland formation: scoring leads to new prognostic groups in World Health Organization low-grade colorectal cancer with impact on survival. **2019**, 89, 81-89	9
1240	Prognostic role of immune infiltrates in breast ductal carcinoma in situ. **2019**, 177, 17-27	21
1239	Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer. **2019**, 17, 5050-5056	6
1238	MHC/HLA Class I Loss in Cancer Cells. **2019**, 1151, 15-78	35
1237	Tumor cell-derived TGF-β at tumor center independently predicts recurrence and poor survival in oral squamous cell carcinoma. **2019**, 48, 696-704	5
1236	PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma. **2019**, 19, 503	12
1235	Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. **2019**, 7, 139	54
1234	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. **2019**, 9, 8572	14
1233	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study. **2019**, 114, 76-88	25
1232	The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. **2019**, 475, 13-23	16
1231	T-bet lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. **2019**, 176, 569-577	9
1230	Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. **2019**, 21, 65	37
1229	Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. **2019**, 9, 452	24
1228	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. **2019**, 176, 699-708	13
1227	Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population. **2019**, 41, 69-78	10
1226	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. **2019**, 25, 4644-4655	41
1225	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. **2019**, 20, 363-369.e2	16
1224	Clinical significance of CD8 T cell immunoreceptor with Ig and ITIM domains in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. **2019**, 8, e1593807	18

1223	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Annals of Oncology*, **2019**, 30, 1279-1288	10.3	220
1222	Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. **2019**, 17, 2647-2656		26
1221	Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab. **2019**, 38, 57-65		1
1220	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. **2019**, 79, 3466-3478		16
1219	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. **2019**, 7, 1025-1035		42
1218	Expression of Autotaxin?Lysophosphatidate Signaling-Related Proteins in Breast Cancer with Adipose Stroma. **2019**, 20,		6
1217	Expression and the molecular forms of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase 9 in canine mammary tumours. **2019**, 17, 427-438		3
1216	Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. **2019**, 7, 88		22
1215	Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. **2019**, 47, 1036-1042		7
1214	The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast. **2019**, 152, 169-176		6
1213	Cytological tumour cell characteristics and reactive small lymphocytes influence patient prognosis in acute and lymphoma type adult T-cell leukaemia/lymphoma. **2019**, 30, 402-412		1
1212	Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: personalised treatments for patients with early breast cancer. **2019**, 13, 924		13
1211	Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?. **2019**, 8,		5
1210	Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer. **2019**, 16, 195-206		7
1209	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. **2019**, 111, 867-871		24
1208	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. **2019**, 25, 5002-5014		120
1207	Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. **2019**, 46, 2713-2720		11
1206	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. **2019**, 35, 428-440.e5		239

| 1205 | A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. **2019**, 26, 1925-1933 | 17 |

| 1204 | Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer. **2019**, 111, 742-746 | 10 |

| 1203 | Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. **2019**, 9, 3461 | 6 |

| 1202 | Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. **2019**, 175, 605-615 | 8 |

| 1201 | Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. **2019**, 26, 573-580 | 6 |

| 1200 | Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients. **2019**, 14, e0212527 | 0 |

| 1199 | Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. **2019**, 12, 739-748 | 1 |

| 1198 | Current Landscape of Immunotherapy in Breast Cancer: A Review. **2019**, 5, 1205-1214 | 143 |

| 1197 | T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. *Annals of Oncology*, **2019**, 30, 934-944 | 10.3 | 8 |

| 1196 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. **2019**, 7, 90 | 40 |

| 1195 | Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation. **2019**, 71, 224-232 | 2 |

| 1194 | Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues. **2019**, 176, 75-85 | 2 |

| 1193 | Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. **2019**, 37, 559-569 | 282 |

| 1192 | Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. **2019**, 37, 1179-1187 | 21 |

| 1191 | BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. **2019**, 450, 88-97 | 21 |

| 1190 | Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry. **2019**, 25, 3054-3062 | 28 |

| 1189 | Blockade of PDGFR circumvents resistance to MEK-JAK inhibition via intratumoral CD8 T-cells infiltration in triple-negative breast cancer. **2019**, 38, 85 | 10 |

| 1188 | Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. **2019**, 19, 120 | 18 |

1187   Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. **2019**, 9, 1583   27

1186   The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. *Annals of Oncology*, **2019**, 30, 575-581   10.3   8

1185   Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. **2019**, 20, 371-382   200

1184   Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. **2019**, 25, 4422-4430   2

1183   Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer. **2019**, 124, 581-587   17

1182   Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. **2019**, 42, 343-356   9

1181   Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. **2019**, 21, 25   20

1180   Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. **2019**, 21, 28   42

1179   Is there value of tumor stromal infiltrating lymphocytes for response assessment to chemoradiation in esophageal squamous cell carcinoma?. **2019**, 7, S283

1178   The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma. **2019**, 14, e0224430   12

1177   Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. **2019**, 11,   7

1176   Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. **2019**, 9, 16662   21

1175   Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients - a randomized trial. **2019**, 19, 1076   6

1174   Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. **2019**, 3,   7

1173   Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications. **2019**, 9, 1328   9

1172   Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. **2019**, 21, 151   14

1171   Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Annals of Oncology*, **2019**, 30, 1941-1949   10.3   78

1170   Immunotherapy in Triple-Negative Breast Cancer: Present and Future. **2019**, 11, 259-271   17

1169	Risk stratification according to stage and pathology. **2019**, 48 Suppl 1, S23-S25		1
1168	Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). **2019**, 48 Suppl 1, S44-S48		26
1167	Assessment of Tumor-infiltrating Lymphocytes Predicts the Behavior of Early-stage Oral Tongue Cancer. **2019**, 43, 1392-1396		21
1166	Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. **2019**, 26, 221-234		11
1165	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. **2021**, 274, e150-e159		3
1164	Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer. **2019**, 67, 469-477		1
1163	Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy. **2019**, 11, 10791-10800		6
1162	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.. **2019**, 3, 1-6		4
1161	Sparse Autoencoder for Unsupervised Nucleus Detection and Representation in Histopathology Images. **2019**, 86, 188-200		72
1160	Breast Cancer. **2019**, 157-167		
1159	Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer. **2019**, 25, 1526-1534		87
1158	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. **2019**, 39, 226-238		17
1157	Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. **2019**, 44, 29-32		29
1156	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. **2019**, 21, 307-317		17
1155	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Annals of Oncology*, **2019**, 30, 236-242	10.3	70
1154	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. **2019**, 64, 025017		14
1153	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. **2019**, 19, 113-125.e4		5
1152	Progress in Tumor-Associated Macrophages: From Bench to Bedside. **2019**, 3, e1800232		7

1151	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. **2019**, 474, 159-168	15
1150	Recent advances in breast cancer research impacting clinical diagnostic practice. **2019**, 247, 552-562	21
1149	Prognostic Utility of Tumor-Infiltrating Lymphocytes in Noncolorectal Gastrointestinal Malignancies. **2019**, 27, 263-267	2
1148	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. **2019**, 174, 55-63	2
1147	Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. **2019**, 75, 354-364	3
1146	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. **2019**, 68, 467-478	20
1145	Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. **2019**, 174, 627-637	6
1144	Colorectal Cancer Biomarkers in the Era of Personalized Medicine. **2019**, 9,	27
1143	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. **2019**, 108, 111-119	7
1142	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. *Annals of Oncology*, **2019**, 30, 418-423	10.3 40
1141	PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. **2019**, 86, 108-114	14
1140	Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. **2019**, 58, 363-370	16
1139	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. **2019**, 5, 334-342	127
1138	Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. *Annals of Oncology*, **2019**, 30, 13-16	10.3 8
1137	A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients. **2019**, 299, 239-246	4
1136	PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. **2019**, 173, 533-543	19
1135	Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results. **2019**, 85, 27-32	7
1134	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. **2019**, 173, 255-266	48

1133	Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. **2019**, 72, 157-164	29
1132	Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma. **2019**, 32, 412-423	8
1131	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. **2019**, 38, 2814-2829	45
1130	Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy. **2019**, 25, 1341-1347	
1129	Tumor inherent interferons: Impact on immune reactivity and immunotherapy. **2019**, 118, 42-47	13
1128	Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. **2020**, 271, 693-700	92
1127	The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History. **2020**, 26, 1221-1228	2
1126	Do Decreased Breast Microcalcifications After Neoadjuvant Chemotherapy Predict Pathologic Complete Response?. **2020**, 20, e82-e88	3
1125	Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations. **2020**, 26, 997-1006	9
1124	Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. **2020**, 220, 88-96	14
1123	The Role of CXCL13 and CXCL9 in Early Breast Cancer. **2020**, 20, e36-e53	14
1122	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. **2020**, 33, 354-366	17
1121	Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer. **2020**, 38, 4.e7-4.e15	1
1120	Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. **2020**, 50, 141-148	17
1119	Tumor-Infiltrating CD1a DCs and CD8/FoxP3 Ratios Served as Predictors for Clinical Outcomes in Tongue Squamous Cell Carcinoma Patients. **2020**, 26, 1687-1695	6
1118	Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. **2020**, 60, 285-293	9
1117	Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer. **2020**, 26, 1499-1510	4
1116	The Cancer Immunotherapy Biomarker Testing Landscape. **2020**, 144, 706-724	30

1115	Tumor-infiltrating lymphocyte-derived MLL2 independently predicts disease-free survival for patients with early-stage oral squamous cell carcinoma. **2020**, 49, 126-136	5
1114	Clonality, Antigen Recognition, and Suppression of CD8 T Cells Differentially Affect Prognosis of Breast Cancer Subtypes. **2020**, 26, 505-517	13
1113	Diverse histomorphology of HER2-positive breast carcinomas based on differential ER expression. **2020**, 76, 560-571	4
1112	Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. **2020**, 146, 1851-1861	3
1111	Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer. **2020**, 46, 77-84	4
1110	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. **2020**, 26, 738-745	19
1109	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. **2020**, 26, 657-668	39
1108	Microsatellite instability in Japanese female patients with triple-negative breast cancer. **2020**, 27, 490-498	8
1107	Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer. **2020**, 476, 701-709	3
1106	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. **2020**, 13, 186-192	6
1105	Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration. **2020**, 28, 767-775	2
1104	A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. **2020**, 76, 661-670	
1103	Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer. **2020**, 22, 1117-1125	
1102	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. **2020**, 13, 410-422	25
1101	Correlation between F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. **2020**, 123, 108773	10
1100	Immune stromal features in cervical squamous cell carcinoma are prognostic factors for distant metastasis: A retrospective study. **2020**, 216, 152751	3
1099	PD-L1 expression and infiltration by CD4 and FoxP3 T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis. **2020**, 76, 714-721	6
1098	CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. **2020**, 476, 569-576	10

1097	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. **2020**, 26, 2704-2710	12
1096	High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. **2020**, 122, 245-257	9
1095	Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients. **2020**, 44, 536-544	23
1094	Triple-negative breast cancer-Role of immunology: A systemic review. **2020**, 26, 995-999	21
1093	Higher densities of tumour-infiltrating lymphocytes and CD4 T cells predict recurrence and progression of ductal carcinoma in situ of the breast. **2020**, 76, 852-864	12
1092	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. **2020**, 26, 6523-6534	4
1091	Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. **2020**, 39, e104063	66
1090	Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer. **2020**, 17, 529-541	2
1089	Prognostic Significance of Interferon-and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. **2020**, 21,	3
1088	Age-related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. **2020**, 9, e1184	8
1087	Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. **2020**, 5, e000843	5
1086	Performance of Automated Dissection on Formalin-Fixed Paraffin-Embedded Tissue Sections for the 21-Gene Recurrence Score Assay. **2020**, 19, 1533033820960760	1
1085	Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis. **2020**, 17, e1003292	8
1084	The immunologic aspects in hormone receptor positive breast cancer. **2020**, 25, 100207	1
1083	CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. **2020**, 21,	56
1082	Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. **2020**, 139, 119-134	11
1081	The genomic landscape of metastatic histologic special types of invasive breast cancer. **2020**, 6, 53	10
1080	Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. **2020**, 12,	39

1079 — Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. **2020**, 91, 102115 — 15

1078 — Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?. **2020**, 41, 1671-1681 — 5

1077 — Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer. **2020**, 10, 1787 — 12

1076 — The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis. **2020**, 9, 8333-8344 — 28

1075 — Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial. **2020**, 25, e1909-e1920 — 8

1074 — Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer. **2020**, 49, 151634 — 5

1073 — Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli. **2020**, 22, 576-589 — 3

1072 — Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. **2020**, 2020, 9235638 — 25

1071 — Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group. **2020**, 112, 524-534 — 1

1070 — A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. **2020**, 22, 76 — 15

1069 — Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma. **2020**, 26, 2733-2745 — 5

1068 — Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis. **2020**, 216, 153120 — 7

1067 — Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions. **2020**, 19, 1533033820943246 — 4

1066 — Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). **2020**, 12, — 34

1065 — Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). **2020**, 11, 5824 — 17

1064 — Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy. **2020**, — 8

1063 — SARS-CoV-2´cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes. **2020**, 24, 100844 — 0

1062 — Opportunities for Antigen Discovery in Metastatic Breast Cancer. **2020**, 11, 570049

1061	Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients. **2020**, 33, 137-144	
1060	The Proportion of Tumour-Stroma in Metastatic Lymph Nodes is An Accurately Prognostic Indicator of Poor Survival for Advanced-Stage Colon Cancers. **2020**, 26, 2755-2764	2
1059	Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study. **2020**, 22, 78	3
1058	Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images. **2020**, 15, 100	17
1057	Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. **2020**, 21, 1155-1164	98
1056	Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. **2020**, 183, 697-704	0
1055	Molecular biology of breast cancer. **2020**, 449-461	
1054	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. **2020**, 21, 1455-1464	20
1053	The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. **2020**, 21,	9
1052	Establishment of an Endoscopy-Guided Minimally Invasive Orthotopic Mouse Model of Colorectal Cancer. **2020**, 12,	1
1051	A role for the immune system in advanced laryngeal cancer. **2020**, 10, 18327	6
1050	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. **2020**, 34, 611-623	21
1049	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. **2020**, 6, 1598-1605	28
1048	A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer. **2020**, 53, 212-220	11
1047	Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams. **2020**, 21,	13
1046	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. **2020**, 12,	4
1045	Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC. **2020**, 12,	0
1044	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. **2020**, 26, 6254-6265	10

1043	The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. **2020**, 17, e1003263	19
1042	Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. **2020**, 123, 1665-1672	10
1041	The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. **2020**, 6, 34	1
1040	Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma. **2020**, 10, 1486	5
1039	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. **2020**, 12,	62
1038	An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer. **2020**, 9, 1792038	5
1037	VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. **2020**, 34, 2641-2646	2
1036	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features în invasive micropapillary breast carcinoma with long-term outcomes. **2020**, 184, 985-998	5
1035	Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis. **2020**, 20, 194	3
1034	Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1 CD8 and CD8 T cells as predictive of response to neoadjuvant chemotherapy in breast cancer. **2020**, 11, 2941-2954	3
1033	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. **2020**, 22, 91	12
1032	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. **2020**, 26, 5668-5681	17
1031	Tumor Infiltrating Lymphocytes in Pet Rabbit Mammary Carcinomas: A Study with Relevance to Comparative Pathology. **2020**, 10,	1
1030	TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up. **2020**, 12,	5
1029	Regulatory T cell and activated natural killer cell infiltration in hepatocellular carcinoma: immune cell profiling using the CIBERSORT. **2020**, 8, 1483	5
1028	Tumour Stroma Ratio Assessment Using Digital Image Analysis Predicts Survival in Triple Negative and Luminal Breast Cancer. **2020**, 12,	11
1027	Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients. **2020**, 21,	2
1026	Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients. **2020**, 2020, 5618786	19

1025	The pancancer landscape of Wnt family expression reveals potential biomarkers in urinary system tumors. **2021**, 28, 1035-1045	0
1024	Assessment of PD-L1 expression and tumor-infiltrating lymphocytes (TILs) across molecular subtypes of triple-negative breast cancer. **2020**, 26, 2424-2427	2
1023	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. **2020**, 11, 6335	15
1022	Impact of Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. **2020**, 12,	6
1021	Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice. **2020**, 10, 20100	5
1020	Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?. **2020**, 21,	4
1019	High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision. **2020**, 216, 153283	1
1018	Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer. **2020**, 107, 1057-1067	14
1017	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. **2020**, 33, 1753-1763	10
1016	Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma. **2020**, 9, 428-436	3
1015	Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. **2020**, 8, 844-850	9
1014	Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer. **2020**, 27, 1007-1016	11
1013	The integration of proportion and cell counts of stromal, not intratumoral, PD-1+ tumor-infiltrating lymphocytes has prognostic significance in esophageal squamous cell carcinoma. **2021**, 34,	
1012	Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer. **2020**, 6, 238-251	4
1011	Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes. **2020**, 12,	9
1010	Association of body composition with survival and inflammatory responses in patients with non-metastatic nasopharyngeal cancer. **2020**, 108, 104771	8
1009	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. **2020**, 33, 2198-2207	9
1008	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. **2020**, 6, 15	8

1007	Association of TILs with clinical parameters, Recurrence Score⬜ results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial. **2020**, 22, 47	6
1006	Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images. **2020**, 9, 4864-4875	5
1005	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. **2020**, 6, 16	47
1004	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. **2020**, 6, 17	54
1003	L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas. **2020**, 73, 748-753	2
1002	Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data. **2020**, 4, 480-490	16
1001	Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer. **2020**, 69, 2381-2391	3
1000	Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression. **2020**, 477, 825-834	3
999	Influences of preoperative metformin on immunological factors in early breast cancer. **2020**, 86, 55-63	3
998	Immuno-Oncology, Imaging Biomarkers and Response to Chemotherapy in Cancer Treatment. **2020**,	
997	Comparison of Nottingham Prognostic Index, PREDICT and PrognosTILs in Triple Negative Breast Cancer -a Retrospective Cohort Study. **2020**, 26, 2443-2450	2
996	Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma. **2020**, 13, 65	6
995	Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes. **2020**, 21,	6
994	The role of cancer-related inflammation for prediction of poor survival in postmenopausal female patients with stage II/III colon cancer. **2020**, 85, 106624	2
993	Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. **2020**, 33, 2473-2482	12
992	Molecular evaluation of chronic restrain stress in mice model of non metastatic fibrosarcoma. **2020**, 51, 367-374	1
991	Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. **2020**, 69, 2247-2257	7
990	DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis. **2020**, 12,	9

989	Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma. **2020**, 108, 104836	12
988	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. **2020**, 52, 515-521	3
987	Advances in quantitative immunohistochemistry and their contribution to breast cancer. **2020**, 20, 509-522	4
986	Pitfalls and controversies in pathology impacting breast cancer management. **2020**, 20, 205-219	2
985	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. **2020**, 15, e0229955	10
984	Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy. **2020**, 133, 552-560	4
983	TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients. **2020**, 69, 1315-1326	5
982	Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. **2020**, 12,	11
981	CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma. **2020**, 20, 240	9
980	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. **2020**, 157, 599-605	1
979	Tumor infiltrative growth pattern correlates with the immune microenvironment and is an independent factor for lymph node metastasis and prognosis in stage T1 esophageal squamous cell carcinoma. **2020**, 477, 401-408	7
978	Expression of the immune checkpoint VISTA in breast cancer. **2020**, 69, 1437-1446	18
977	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. **2020**, 34, 639-647	9
976	Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. **2020**, 9,	121
975	Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. **2020**, 33, 1182-1192	13
974	Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer. **2020**, 20, 598	7
973	Diversity of Tumor-Infiltrating, T-Cell Abundance in Solid Cancers. **2020**, 9,	12
972	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. **2020**, 33, 2221-2232	10

971	Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration. **2020**, 22, 73		8
970	Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer. **2020**, 20, 584		6
969	Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. **2020**, 22, 69		16
968	Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer. **2020**, 183, 49-59		4
967	Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer. **2020**, 12, 1824-1842		10
966	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. **2020**, 183, 347-354		22
965	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. **2020**, 136, 7-15		13
964	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. *Annals of Oncology*, **2020**, 31, 1216-1222	10.3	52
963	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. **2020**, 6, 4		19
962	Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. **2020**, 69, 689-702		7
961	PD-L1 expression and survival in p16-negative and -positive squamous ́cell carcinomas of the vulva. **2020**, 146, 569-577		6
960	Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. **2020**, 180, 369-377		19
959	Invasive breast cancer: Current perspectives and emerging views. **2020**, 70, 242-252		8
958	TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial). **2020**, 38, 1539-1548		46
957	Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification. **2020**, 19, 690-700		1
956	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. **2020**, 26, 2783-2788		12
955	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. *Annals of Oncology*, **2020**, 31, 569-581	10.3	115
954	ATM kinase regulates tumor immunoreactions in lymphocyte-predominant breast cancer through modulation of NKG2D ligand and TNF cytokines on tumor cells. **2020**, 53, 210-220		1

953   Graph-based description of tertiary lymphoid organs at single-cell level. **2020**, 16, e1007385   3

952   B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration. **2020**, 87, 179-192   10

951   Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. **2020**, 21, e302-e314   4

950   Tissue-resident memory T cells in breast cancer control and immunotherapy responses. **2020**, 17, 341-348   70

949   Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS. **2019**, 9, 1545   8

948   Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. **2020**, 19, 19   90

947   Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. **2020**, 9, 1677427   5

946   Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.. **2020**, 9, 155-165   1

945   Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. **2020**, 127, 240-250   9

944   Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. **2020**, 10, 643   57

943   A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer. **2020**, 26, 1595-1605   3

942   Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer. **2020**, 180, 311-319   4

941   Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. **2020**, 18, 49   52

940   Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. **2020**, 50, 56-63   3

939   [Immunoncology and tumor infiltrating lymphocytes-new strategies for therapy and diagnosis of breast cancer]. **2020**, 41, 248-253

938   Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer. **2020**, 190, 1491-1504   26

937   Diagnostic value of F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8tumour-infiltrating lymphocytes in oral squamous cell carcinoma. **2020**, 122, 1686-1694   18

936   Stromal tumour-infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma. **2020**, 76, 1095-1101   5

935 | Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer. **2020**, 24, 5501-5514 | 8

934 | Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. **2020**, 39, 61-69 | 4

933 | Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. **2020**, 12, | 9

932 | Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer. **2020**, 77, 560-569 | 3

931 | Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. **2020**, 77, 79-91 | 12

930 | Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. **2020**, 9, 66 | 2

929 | A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. **2020**, 84, e13244 | 3

928 | Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. **2020**, 69, 1549-1564 | 9

927 | Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis. **2020**, 10, 6598 | 16

926 | Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 T-cell functionality. **2020**, 8, | 11

925 | The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. **2020**, 87, 125-142 | 21

924 | Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. **2020**, 15, e0222551 | 14

923 | Antibody Supervised Training of a Deep Learning Based Algorithm for Leukocyte Segmentation in Papillary Thyroid Carcinoma. **2021**, 25, 422-428 | 7

922 | T-cell-based breast cancer immunotherapy. **2021**, 72, 90-101 | 12

921 | Pathology of triple negative breast cancer. **2021**, 72, 136-145 | 27

920 | The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. **2021**, 21, e63-e73 | 23

919 | Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. **2021**, 113, 146-153 | 11

918 | Histopathologic features of breast cancer in Li-Fraumeni syndrome. **2021**, 34, 542-548 | 10

| 917 | IL-23R in laryngeal cancer: a cancer immunoediting process that facilitates tumor cell proliferation and results in cisplatin resistance. **2021**, 42, 118-126 | 7 |

| 916 | Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. **2021**, 22, e415-e424 | 5 |

| 915 | Development of Prediction Model Including MicroRNA Expression for Sentinel Lymph Node Metastasis in ER-Positive and HER2-Negative Breast Cancer. **2021**, 28, 310-319 | 10 |

| 914 | Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocytes and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. **2021**, 16, 328-334 | 2 |

| 913 | Immunotherapeutic strategies in breast cancer: A clinical update. **2021**, 123, 710-717 | 2 |

| 912 | Immune factors associated with the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer. **2021**, 14, 100927 | 3 |

| 911 | Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy. **2021**, 185, 629-638 | 0 |

| 910 | Artificial intelligence and the interplay between tumor and immunity. **2021**, 211-235 | 0 |

| 909 | Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. **2021**, 81, 50-57 | 14 |

| 908 | Stromal categorization in early oral tongue cancer. **2021**, 478, 925-932 | 5 |

| 907 | The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. **2021**, 6, 697-711 | 5 |

| 906 | Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma. **2021**, 43, 534-543 | 2 |

| 905 | A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. **2021**, 78, 567-577 | 9 |

| 904 | Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. **2021**, 478, 669-678 | 6 |

| 903 | Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis. **2021**, 51, 595-604 | 0 |

| 902 | Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis. **2021**, 123, 89-95 | 3 |

| 901 | Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma. **2021**, 26, 63-69 | 2 |

| 900 | Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. **2021**, 108, 84-92 | 1 |

899	Immunohistochemical expression of Neurogenic Locus Notch Homolog 4 (Notch4) in invasive breast carcinoma: Correlation with clinicopathological parameters and immunohistochemical-based subtypes. **2021**, 34, 77-87	
898	Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N⋅SAS-BC⋅01 trial and CUBC trial). **2021**, 186, 135-147	1
897	Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. **2021**, 34, 875-882	5
896	Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP). **2021**, 27, 975-982	20
895	Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer. **2021**, 50, 151657	10
894	High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers. **2021**, 15, 429-461	4
893	Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer. **2021**, 14, 100986	2
892	Tumor-Infiltrating Lymphocytes in Low-Risk Patients With Breast Cancer Treated With Single-Dose Preoperative Partial Breast Irradiation. **2021**, 109, 1325-1331	2
891	Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. **2021**, 55, 7-15	2
890	HookNet: Multi-resolution convolutional neural networks for semantic segmentation in histopathology whole-slide images. **2021**, 68, 101890	20
889	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. **2021**, 26, e382-e393	11
888	Characterising the immune microenvironment in liposarcoma, its impact on prognosis⋅and the impact of radiotherapy. **2021**, 123, 117-126	3
887	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. **2021**, 26, 99-e217	12
886	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. **2021**, 64, 372-388	5
885	Exhaustion of tumour-infiltrating T-cell⋅receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma. **2021**, 193, 138-149	5
884	High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. **2021**, 34, 478-489	6
883	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. **2021**, 70, 519-531	3
882	PD-L1 status in breast cancer: Current view and perspectives. **2021**, 72, 146-154	23

881	Non-coding RNAs Related to Cardiometabolic Diseases and Associated to Cancer. **2021**, 149-211	
880	Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis. **2021**, 20, 15330338211034265	2
879	Significance of HER2 in Microinvasive Breast Carcinoma. **2021**, 156, 155-165	1
878	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. **2021**, 185, 557-566	5
877	Defining Breast Cancer. **2021**, 1-31	
876	Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis. **2021**, 11, e044163	4
875	Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study). **2021**, 10, 1861737	1
874	Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors. **2021**, 35, 1277-1283	2
873	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. **2021**, 24, 359-366	0
872	Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. **2020**, 11, 563258	3
871	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion. **2021**, 113, 1036-1043	12
870	Longitudinal Intravital Imaging of Tumor-Infiltrating Lymphocyte Motility in Breast Cancer Models. **2021**, 24, 463-473	0
869	Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker for Assessing the Level of Tumor-Infiltrating Lymphocytes: Value in Molecular Subtypes of Breast Cancer. **2020**, 10, 611571	6
868	A Cervical Histopathology Image Clustering Approach Using Graph Based Features. **2021**, 2, 1	0
867	Enhanced humoral immunity in breast cancer patients with high serum concentration of anti-HER2 autoantibody. **2021**, 10, 1418-1430	2
866	Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links VI2 1T Cell Alterations with Lymph Node Invasion. **2021**, 13,	0
865	Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. **2021**, 23, 6	17
864	Single Cell Genomics for Tumor Heterogeneity. **2021**, 1187, 205-214	

863	Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma. **2021**, 13,	7
862	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. **2021**, 22,	7
861	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. **2021**, 13,	8
860	Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. **2021**, 145, 1132-1137	4
859	Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer. **2021**, 13, 17588359211006680	3
858	Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. **2021**, 10,	26
857	The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes. **2021**, 13,	1
856	Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3. **2021**, 12, 561793	7
855	Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. **2021**, 16, e0247238	6
854	Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. **2021**, 186, 687-697	5
853	A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis. **2021**, 15, 1345-1357	2
852	A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling. **2020**, 11, 616188	0
851	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. **2021**, 12,	4
850	Clinicopathological Correlates of T Cell Infiltration in Triple-Negative Breast Cancer. **2021**, 13,	3
849	Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation. **2021**, 7, 191-202	2
848	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. **2021**, 27, 2584-2591	10
847	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. **2021**, 113, 1005-1016	56
846	Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore. **2021**, 124, 1421-1427	7

845	The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. **2021**, 14, 100973	5
844	Protein-based immune profiles of basal-like vs. luminal breast cancers. **2021**, 101, 785-793	2
843	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. **2021**, 7, 12	2
842	Advanced Approaches to Breast Cancer Classification and Diagnosis. **2020**, 11, 632079	15
841	CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. **2021**, 11, 4691	13
840	Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study. **2021**, 16, e0245725	3
839	Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues. **2021**, 21, e738-e747	4
838	Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer. **2021**, 11, 590414	4
837	Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. **2021**, 13, 1571-1580	5
836	Proposal of a scoring system for predicting pathological risk based on a semiautomated analysis of whole slide images in oral squamous cell carcinoma. **2021**, 43, 1581-1591	2
835	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. **2021**, 5, 23	5
834	Overview of recent advances in metastatic triple negative breast cancer. **2021**, 12, 164-182	9
833	Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. **2021**, 11, 616629	4
832	Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study. **2021**, 21, 260	1
831	High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. **2021**, 23, 40	3
830	Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer. **2021**, 21, 239	13
829	Tumor-infiltrating lymphocytes in tissue material combined with systemic lymphocyte inflammation in patients with colorectal cancer. **2021**, 14, 97	0
828	Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists. **2021**, 36, 1765-1779	2

809 | Tumor-infiltrating CD8 T cell antitumor efficacy and exhaustion: molecular insights. **2021**, 26, 951-967 | 7

808 | Expression of cancer testis antigens in thymic epithelial tumors. **2021**, 71, 471-479 | 2

807 | Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. **2021**, 11, 7550 | 2

806 | Determination of HLA-DR level in cytotoxic T lymphocytes: a new validated tool to predict breast cancer response to treatment.

805 | Immune-related biomarkers in triple-negative breast cancer. **2021**, 28, 792-805 | 10

804 | Immunology and immunotherapy in the complex treatment of malignant tumors. **2021**, 248-257 | 0

803 | Tumor infiltrating lymphocyte signature is associated with single nucleotide polymorphisms and predicts survival in esophageal squamous cell carcinoma patients. **2021**, 13, 10369-10386

802 | Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. **2021**, 12, 2186 | 21

801 | Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology. **2021**, 1875, 188520 | 7

800 | Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics. **2021**, 56, 78-87 | 3

799 | Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer. **2021**, 21, e681-e687 | 2

798 | Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. **2021**, 13, | 4

797 | Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in -Mutated Breast Cancer: Analysis. **2021**, 27, 633243 | 0

796 | Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer. **2021**, 22, | 0

795 | Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice. **2021**, 79, 47-56 | 3

794 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. **2021**, 27, 820-832 | 57

793 | Immune Crosstalk Between Lymph Nodes and Breast Carcinomas, With a Focus on B Cells. **2021**, 8, 673051 | 3

792 | Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. **2021**, 23, 61 | 2

773	MGMT Immunohistochemical Expression in Colorectal Carcinoma and its Correlation with Tumor Progression. **2021**, 9, 244-251	
772	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8 Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. **2021**, 12, 680973	3
771	Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection. **2021**, 1945998211013765	2
770	CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. **2021**, 13,	4
769	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. **2021**, 21, 539-551	4
768	The Immunology of Hormone Receptor Positive Breast Cancer. **2021**, 12, 674192	13
767	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. **2021**, 13,	11
766	Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma. **2021**, 51, 1985-1995	2
765	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. **2021**,	21
764	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). **2021**, 27, 5828-5837	5
763	Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. **2021**, 189, 187-202	5
762	A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy. **2021**, 11, 635237	5
761	Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers. **2021**, 13,	3
760	Neoantigens elicit T cell responses in breast cancer. **2021**, 11, 13590	3
759	Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer. **2021**, 27, 1609795	0
758	Evaluation of Tumor Elasticity and Clinicopathologic Factors Affecting Neoadjuvant Chemotherapy Response in Patients with Breast Cancer. **2021**, 9, 16-25	
757	Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent. **2021**, 10, 5712-5720	1
756	Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients. **2021**, 16, e0253176	5

| 737 | Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. **2021**, | 5 |

| 736 | Prognostic Value of Tumor-Infiltrating Lymphocytes and Tertiary Lymphoid Structures in Epstein-Barr Virus-Associated and -Negative Gastric Carcinoma. **2021**, 12, 692859 | 2 |

| 735 | Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. **2021**, 7, 84 | 2 |

| 734 | Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. **2021**, 7, 96 | 7 |

| 733 | Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. **2021**, 11, 678315 | 4 |

| 732 | Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. **2021**, | 0 |

| 731 | Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer. **2021**, 11, 6788 | 3 |

| 730 | MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. **2021**, 9, | 6 |

| 729 | MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. **2021**, | 0 |

| 728 | Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer. **2021**, 21, 1299-1301 | 1 |

| 727 | Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. **2021**, 34, 2130-2140 | 2 |

| 726 | Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. **2021**, 7, 86 | 1 |

| 725 | Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer. **2021**, 13, | 1 |

| 724 | BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. **2021**, | 1 |

| 723 | Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment. **2021**, | 3 |

| 722 | The impact of site-specific digital histology signatures on deep learning model accuracy and bias. **2021**, 12, 4423 | 10 |

| 721 | Relationship Between Prognostic Nutritional Index and Mortality in Overweight or Obese Patients with Cancer: A Multicenter Observational Study. **2021**, 14, 3921-3932 | 0 |

| 720 | A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. **2021**, 21, 901 | 5 |

719   Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration. **2021**, 19, 89   2

718   Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. **2022**, 45, 35-42   0

717   The identification of tumor-infiltrating lymphocytes in patients with stomach cancer. **2021**, 23, 307-312

716   Interpreting the Complex Landscape of Immune-Tumor Interface. **2021**, 27, 5446-5448   1

715   Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase. **2021**, 1   2

714   Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics. **2021**,   2

713   [2021´update of the GEFPICS' recommendations for HER2´status assessment in invasive breast cancer in France]. **2021**, 41, 507-520   1

712   Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. **2021**, 1876, 188587   4

711   A Computational Tumor-Infiltrating Lymphocyte Assessment Method Comparable with Visual Reporting Guidelines for Triple-Negative Breast Cancer. **2021**, 70, 103492   5

710   Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. **2021**, 9,   7

709   Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. **2021**, 10,

708   Counterbalance of Foxp3 and IDO expression at different tumor stages in aggressive breast cancer subtypes.

707   Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. **2021**, 7, 110   5

706   Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. **2021**, 22, 1151-1161   32

705   The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications. **2021**,   1

704   Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. **2021**, 13,   10

703   Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. **2021**, 125, 1388-1398   4

702   Breast Cancer Heterogeneity. **2021**, 11,   2

701	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. **2021**, 101, 1561-1570	0
700	Human Epidermal Growth Factor Receptor Type 2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes. **2021**,	1
699	Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer. **2021**, 19, 348	1
698	Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer. **2021**, 13,	1
697	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. **2021**, 13,	3
696	Editorial Comment: Tailored Therapies in Patients With HER2+ Breast Cancer Could be Achieved by Using TIL Predictors, Significantly Improving Patient Outcomes. **2021**,	
695	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. **2021**, 13,	0
694	Comprehensive Analysis to Identify Enhancer-Regulated Inflammation-Associated Genes in Lung Adenocarcinoma. **2021**, 13, 7115-7129	1
693	Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4 T Cells in the Central Region of pMMR CRC. **2021**, 11, 724232	0
692	YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer. **2021**, 10, 2799-2814	1
691	Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development. **2021**, 1-15	3
690	Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. **2021**, 11, 19154	1
689	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. **2021**, 13,	1
688	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. **2021**, 13,	2
687	Necroptosis in Esophageal Squamous Cell Carcinoma: An Independent Prognostic Factor and Its Correlation with Tumor-Infiltrating Lymphocytes. **2021**, 13,	4
686	Phase I/II trial of palbociclib, pembrolizumab´and letrozole in patients with hormone receptor-positive metastatic breast cancer. **2021**, 154, 11-20	6
685	Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer. **2021**, 154, 217-226	0
684	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. **2021**, 7, 124	1

683   Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. **2021**, 189, 599-606   5

682   Artificial intelligence for solid tumour diagnosis in digital pathology. **2021**, 178, 4291-4315   2

681   Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. **2021**, 10, 7921-7933   1

680   Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients. **2021**, 190, 477-489   1

679   DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. **2021**, 9,   7

678   The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication. **2021**, 12, 618367   1

677   Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. **2021**, 7, 114   2

676   Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer. **2021**, 16, e0257860   1

675   Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer. **2021**, 11, 675533   1

674   Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. **2021**, 11, 582664   3

673   Prognostic impact of tumor-infiltrating lymphocytes in non-small cell lung carcinomas. **2021**, 2184923211042129   2

672   Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice. **2021**, 13,   1

671   Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer. **2021**, 20, 2553-2567   2

670   Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. **2021**, 7, 1360-1367   1

669   A review of immune checkpoint blockade in breast cancer. **2021**, 48, 208-225   2

668   Refining patient selection for breast cancer immunotherapy: beyond PD-L1. **2021**, 6, 100257   4

667   PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection. **2021**, 11, 19555   1

666   Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient. **2021**, 26, 2265-2274

665	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). **2021**, 160, 17-27	1
664	YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. **2021**, 160, 166-174	2
663	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. **2021**, 59, 183-192	4
662	Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?. **2021**, 226, 153606	1
661	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. **2021**, 131,	10
660	The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. **2021**, 41, 101134	22
659	Application of immunotherapy based on dendritic cells stimulated by tumor cell-derived exosomes in a syngeneic breast tumor mouse model. **2021**, 28, 101136	
658	Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes. **2021**, 2265, 515-528	
657	Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype. **2021**, 28, 822-828	1
656	Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer. **2021**, 23, 2	14
655	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. **2021**, 10, 1929724	4
654	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. **2021**, 27, 250-255	28
653	VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer. **2020**, 10, 583966	8
652	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. **2021**, 10, 1924492	2
651	Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer. **2021**, 23, 4	8
650	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Update for 2020. **2021**, 27, 25-31	7
649	Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. **2020**, 27, 519-526	3
648	Radiomics Model for Evaluating the Level of Tumor-Infiltrating Lymphocytes in Breast Cancer Based on Dynamic Contrast-Enhanced MRI. **2021**, 21, 440-449.e1	3

647	Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer. **2020**, 134, 711-726	12
646	PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer. **2020**, 99, e23418	1
645	Clinical Significance of Immunohistochemical Expression of Neuropeptide Y1 Receptor in Patients With Breast Cancer in Egypt. **2021**, 29, 277-286	2
644	Gene expression markers of Tumor Infiltrating Leukocytes.	5
643	Spatial transcriptomics of tumor microenvironment in formalin-fixed paraffin-embedded breast cancer.	4
642	Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer.	2
641	The Impact of Digital Histopathology Batch Effect on Deep Learning Model Accuracy and Bias.	5
640	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.	3
639	PD-L1 expression in 522 selected sarcomas with subset analysis of recurrent or metastatic matched samples and association with tumour-infiltrating lymphocytes.	0
638	CD20 tumor-infiltrating immune cells and CD204 M2 macrophages are associated with prognosis in thymic carcinoma. **2020**, 111, 1921-1932	11
637	Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer. **2020**, 111, 2647-2654	14
636	Joint Region and Nucleus Segmentation for Characterization of Tumor Infiltrating Lymphocytes in Breast Cancer. **2019**, 10956,	14
635	A combination of intra- and peritumoral features on baseline CT scans is associated with overall survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a multi-agent multi-site study. **2019**,	2
634	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. **2020**, 8,	18
633	Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. **2020**, 8,	31
632	Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers. **2021**, 81, 1171-1177	5
631	Cancer-Associated Fibroblasts Affect Intratumoral CD8 and FoxP3 T Cells Via IL6 in the Tumor Microenvironment. **2018**, 24, 4820-4833	128
630	T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity. **2020**, 8, 530-543	18

629	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. **2020**, 8, 1508-1519	14
628	Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy. **2021**, 16, 444-451	1
627	Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. **2019**, 4,	41
626	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. **2019**, 129, 1785-1800	125
625	A deep-learning-based prognostic nomogram integrating microscopic digital pathology and macroscopic magnetic resonance images in nasopharyngeal carcinoma: a multi-cohort study. **2020**, 12, 1758835920971416	7
624	Identification of Genes with Prognostic Value in the Breast Cancer Microenvironment Using Bioinformatics Analysis. **2020**, 26, e920212	9
623	Triple-negative breast cancer: recent treatment advances. **2019**, 8,	69
622	Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers. **2015**, 10, e0134965	43
621	Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. **2015**, 10, e0143804	11
620	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. **2016**, 11, e0152500	144
619	Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?. **2016**, 33, 237-246	1
618	as a prognostic marker and its correlation with immune infiltrates in breast cancer. **2019**, 11, 11124-11135	25
617	Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. **2016**, 7, 44395-44405	20
616	Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. **2016**, 7, 59957-59964	14
615	Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. **2016**, 7, 81778-81790	77
614	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. **2017**, 8, 15584-15592	76
613	Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. **2017**, 8, 14759-14769	27
612	Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. **2017**, 8, 103671-103681	52

593	Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization. **2020**, 20, 140	5
592	Circulating microRNAs and their role in the immune response in triple-negative breast cancer. **2020**, 20, 224	5
591	Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples. **2016**, 7, 38	53
590	Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer. **2018**, 61, 181-186	4
589	Evaluation of CD30/CD4/CD8 in triple-negative invasive ductal carcinoma of breast in association with clinicopathological prognostic factors. **2018**, 61, 500-504	2
588	Immunotherapy in breast cancer. **2019**, 18, 2	36
587	Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. **2015**, 49, 355-63	29
586	CD9 Expression in Colorectal Carcinomas and Its Prognostic Significance. **2016**, 50, 459-468	9
585	Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers. **2017**, 49, 313-321	6
584	Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. **2017**, 49, 399-407	50
583	Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study. **2019**, 51, 1336-1346	3
582	Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. **2017**, 9, 293-299	38
581	Comparison of MRI and US in Tumor Size Evaluation of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. **2019**, 15, 119-124	12
580	Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. **2016**, 7, 387-394	25
579	Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. **2020**, 18, 517-521	10
578	Therapeutic strategies to reverse immunosuppressive breast cancer microenvironment. **2016**, 4, 1	2
577	Topography of cancer-associated immune cells in human solid tumors. **2018**, 7,	123
576	Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4 PD-1 and LAG-3. **2021**,	1

575	Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer. **2021**, 15, 252	1
574	Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies. **2021**,	1
573	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. **2021**,	35
572	Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer. **2021**,	0
571	PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. **2021**, 13,	1
570	A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma. **2021**, 256, 174	3
569	Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma. **2021**,	4
568	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. **2021**,	6
567	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. **2021**,	0
566	Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment. **2021**, 1	1
565	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1´+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. **2021**, 17, 4665-4676	0
564	Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer. **2021**, 62, 63-71	1
563	Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.. **2021**, 16, 637-647	2
562	Synchronous Rectal Tumours with Different Molecular and Genetic Phenotypes Occurring in a Patient with Lynch Syndrome. **2021**, 13, 8009-8015	
561	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. **2021**, 1	0
560	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. **2021**, 1	2
559	P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses. **2021**, 12, 2252-2265	1
558	Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. **2021**, 12, 6201	9

557 Tratamiento del cǎcer de mama infiltrante localizado: nuevos desafǒs. **2021**, 57, 1-20

556 Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. **2021**, 10, 71   4

555 Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer. **2016**, 167-186

554 Dǔinition du pronostic des cancers du sein aujourd'hui : intǔration de l'anatomie et de la biologie. **2016**, 189-195

553 Neoadjuvant Systemic Treatment (NST). **2016**, 437-449

552 Immune DNA signature of T-cell infiltration in breast tumor exomes.

551 Prognostic and Predictive Factors in Breast Carcinoma. **2018**, 327-356   1

550 Die Wirkungen der Mistelsubstanz auf das Immunsystem und mǒliche therapeutische Implikationen. **2018**, 71, 265-268   1

549 A watershed and feature-based approach for automated detection of lymphocytes on lung cancer images. **2018**,

548 Novel immune cell subtypes linked to survival among African American women with triple-negative breast cancer.

547 Imprint of parity and age at first birth on the genomic landscape of subsequent breast cancer.

546 Comprehensive analysis of immune evasion in breast cancer by single-cell RNA-seq.   2

545 Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of breast cancer.

544 Encyclopedia of Pathology. **2019**, 1-10

543 Characteristics of inflammatory reactions in the tumor microenvironment of head and neck squamous cell carcinoma. **2019**, 17, 57-63

542 Comparison of Tumor Infiltrating Lymphocyte Density with Histopathological Parameters and Effect on Prognosis in Head and Neck Squamous Cell Cancers. **2020**, 54, 438-443

541 Immunotherapy in Breast Cancer. **2019**, 541-552

540 Prognostic and Predictive Factors. **2019**, 163-172

539	Associations between absolute neutrophil count and lymphocyte-predominant breast cancer.	
538	Phenotyping tumor infiltrating lymphocytes (PhenoTIL) on H&E tissue images: predicting recurrence in lung cancer. **2019**,	
537	Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer. **2019**, 15, 10-29	2
536	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. **2019**, 2, 130-136	1
535	The 2018 Incentive Award of the Okayama Medical Association in Cancer Research (2018 Hayashibara Prize and Yamada Prize). **2019**, 131, 127-130	
534	Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes. **2020**, 12, 3145-3153	1
533	No impact of smoking status on breast cancer tumor infiltrating lymphocytes, response to neoadjuvant chemotherapy and prognosis.	
532	Stromal Tumor Infiltrating Lymphocytes (sTILs) as a putative prognostic marker to identify a responsive subset of TNBC in an Indian Breast Cancer Cohort.	
531	Impact of DAXX and ATRX expression on telomere length and prognosis of breast cancer patients. **2020**, 32, 34	
530	Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. **2021**, 23, 99	3
529	Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma. **2021**, 228, 153677	1
528	Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort. **2021**, 1-10	1
527	Introduction to Digital Pathology from Historical Perspectives to Emerging Pathomics. **2022**, 1-22	0
526	Heterogeneity of circulating tumor cell-associated genomic gains in breast cancer and its association with the host immune response. **2021**,	0
525	Development of prognostic nomograms using institutional data for patients with triple-negative breast cancer. **2021**, 17, 5077-5091	1
524	Collaborative Federated Learning behind Hospitals Firewalls for Predicting Histological Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.	0
523	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. **2021**,	0
522	Characterizing Immune Responses in Whole Slide Images of Cancer With Digital Pathology and Pathomics. **2020**, 8, 133-148	3

521	CLINICAL IMPACT AND PROGNOSTIC VALUE OF TUMOR INFILTRATING LYMPHOCYTES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA. **2020**, 1-4	
520	The prognostic value of lymph node involvement after neoadjuvant chemotherapy is different among breast cancer subtypes.	
519	PROGNOSTIC SIGNIFICANCE OF THE EPITHELIAL-MESENCHYMAL TRANSITION MARKERS AND MORPHOLOGICAL CHARACTERISTICS OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS IN THE DEVELOPMENT OF LYMPHOGENOUS METASTASES. **2020**, 18, 67-74	
518	Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases. **2019**, 18, 4904-4912	2
517	Breast Pathology. **2020**, 185-195	0
516	Reporting Core Biopsies: Lesions That Are Highly Suspicious of Malignancy (B4) or Definitely Malignant (B5). **2020**, 95-219	
515	Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysis.	
514	APOBEC3B expression and its prognostic potential in breast cancer. **2020**, 19, 3205-3214	3
513	PD-1 and PD-L1 are diagnostic biomarkers and PD-L1 a promising therapeutic target in HER2-positive and triple negative normal-like feline mammary carcinoma subtypes.	1
512	Clinicopathologic Features and Prognostic Role of CD3, CD8, and PD-1 positive Tumor-Infiltrating Lymphocytes and the Association with COX-2 Overexpression in Endometrial Carcinoma. **2020**, 13,	0
511	Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer.. **2021**, 1, 309-316	0
510	Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy. **2021**, 21, 1129	2
509	Wound-like tumor periphery in human breast cancer predicts a convergent drug nonresponse.	0
508	PD-1 and PD-L1 Expression in Indian Women with Breast Cancer.. **2022**, 18, 21-29	2
507	VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes. **2021**, 13,	0
506	Multiplexed immunofluorescence identifies high stromal CD68PD-L1 macrophages as a predictor of improved survival in triple negative breast cancer. **2021**, 11, 21608	3
505	Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms. **2021**, 27, 1175	
504	Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers. **2020**, 21, 1008-1025	1

503	Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer.	
502	Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma. **2020**, 111, 337-343	1
501	Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study. **2020**, 8, e9779	1
500	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).	
499	Impact of BRCA mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.	1
498	Breast cancer molecular subtypes: from TNBC to QNBC. **2016**, 6, 1864-1872	57
497	Disease evolution and heterogeneity in bilateral breast cancer. **2016**, 6, 2611-2630	4
496	Highlight report: Relevance of T-cells, B-cells and immune checkpoint factors for prognosis of breast cancer. **2019**, 18, 253-255	
495	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. **2021**, 21, 36	3
494	Endometrial cancer may be part of the MUTYH-associated polyposis cancer spectrum. **2021**, 65, 104385	1
493	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. **2021**, 9,	3
492	Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting. **2021**,	3
491	Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. **2021**, 1-7	6
490	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. **2022**, 23, 23	
489	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. **2021**, 7, 144	0
488	Effector memory cytotoxic CD3/CD8/CD45RO T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. **2021**,	0
487	The Concentration of CMKLR1 Expression on Clinicopathological Parameters of Colorectal Cancer: A Preliminary Study.. **2021**, 57,	0
486	Molecular and clinical characterization of postpartum-associated breast cancer in the Carolina Breast Cancer Study Phase I-III, 1993-2013. **2021**,	1

485	Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer.. **2021**, 15, 1317	1
484	Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer. **2021**, 11, 747012	1
483	The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer. **2021**, 12, 784823	2
482	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. **2021**,	3
481	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. **2021**, 13,	0
480	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. **2021**, 7, 145	0
479	Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients.. **2021**, 8, 761163	1
478	Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate. **2021**, 13,	0
477	Targeting the Wnt signaling pathway for breast cancer bone metastasis therapy. **2021**, 1	
476	An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients with HPV-Associated Oropharyngeal Cancer. **2021**,	1
475	Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. **2022**, 163,	2
474	Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density. **2021**, 14, 5891-5899	0
473	Prognostic markers compared to CD3+TIL in locally advanced nasopharyngeal carcinoma. **2021**, 100, e27956	
472	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. **2021**, 7, 150	17
471	A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study. **2021**, 12, 45	7
470	Peritumoral CD16b positive-neutrophil accumulation strongly correlates with regional lymph node metastasis in thoracic esophageal squamous cell cancer.. **2022**,	
469	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. **2022**, 75, 103801	3
468	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. **2020**, 21, 1-1	3

467	Mammary tumor-derived transplants as breast cancer models to evaluate tumor-immune interactions and therapeutic responses.. **2021**,	
466	Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.. **2022**,	2
465	Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours.. **2022**,	2
464	Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies.. **2022**, 27, 30-39	1
463	Preoperative radiotherapy to optimize immune priming in breast cancer: early results from SIGNAL Trials.. **2022**,	
462	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. **2022**, 1	4
461	A review of prognostic and predictive biomarkers in breast cancer.. **2022**, 1	3
460	The Prognostic Impact of Combined Tumor-Infiltrating Lymphocytes and Pretreatment Blood Lymphocyte Percentage in Locally Advanced Nasopharyngeal Carcinoma.. **2021**, 11, 788497	0
459	The prognostic significant of tumor budding, tumor stroma ratio and tumor-infiltrating lymphocytes in gallbladder adenocarcinoma. **2022**, 12, 1-1	
458	A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.. **2022**, 191, 599	2
457	Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer.. **2022**, 14,	2
456	The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.. **2021**, 11, 706606	1
455	Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A Preliminary Observational Study.. **2022**, 58,	2
454	Histologic-Based Tumor-Associated Immune Cells Status in Clear Cell Renal Cell Carcinoma Correlates with Gene Signatures Related to Cancer Immunity and Clinical Outcomes.. **2022**, 10,	1
453	Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study.. **2022**, 1	0
452	Pathogenesis of Triple-Negative Breast Cancer.. **2022**, 17, 181-204	10
451	An Immune Feature-Based, Three-Gene Scoring System for Prognostic Prediction of Head-and-Neck Squamous Cell Carcinoma.. **2021**, 11, 739182	0
450	MuTILs: explainable, multiresolution computational scoring of Tumor-Infiltrating Lymphocytes in breast carcinomas using clinical guidelines.	1

449	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.. **2022**, JCO2101506	7
448	Lymphocytes and sinus histiocytosis in tumor and matched lymph nodes as predictors of survival in non-small-cell lung cancer.. **2022**,	
447	Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.. **2022**, 57, 151901	2
446	Tumor-infiltrating lymphocytes in breast FNA biopsy cytology: a predictor of tumor-infiltrating lymphocytes in histologic evaluation.. **2022**,	1
445	Limitations and opportunities for tumor infiltrating lymphocytes in breast FNA.. **2022**,	
444	Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex.. **2022**, 1	0
443	CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.. **2022**,	0
442	Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.. **2021**, 23, 114	0
441	PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma. **2021**,	7
440	Multi-omic machine learning predictor of breast cancer therapy response. **2021**,	15
439	Research progress in immunotherapy of NSCLC with EGFR sensitive mutations.. **2022**,	
438	Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T cell infiltration.. **2022**, 26, 27-31	
437	Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.. **2022**, 30, e20210344	
436	PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.. **2022**, 36, 3946320221078433	0
435	New insights into the discovery of drugs for triple-negative breast cancer metastasis.. **2022**, 1-12	0
434	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.. **2022**,	0
433	Association of tumor deposits with tumor-infiltrating lymphocytes and prognosis in gastric cancer.. **2022**, 20, 58	1
432	Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age.. **2022**, 20, 38	1

431	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. **2022**, 13, 896	4
430	The Prognostic Role of Intratumoral Stromal Content in Lobular Breast Cancer.. **2022**, 14,	1
429	Quantitative Analysis of Breast Cancer Tissue Composition and Associations with Tumor Subtype.. **2022**,	0
428	Effect of Early-Stage Human Breast Carcinoma on Monocyte Programming.. **2021**, 11, 800235	3
427	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer.. **2022**, 12, 2742	2
426	Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer.. **2022**, 8, 26	0
425	PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer.. **2022**, 8, eabk3338	0
424	Deep Learning-Based Mapping of Tumor Infiltrating Lymphocytes in Whole Slide Images of 23 Types of Cancer.. **2021**, 11, 806603	5
423	Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.. **2022**, 10,	0
422	A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma.. **2022**,	2
421	Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.. **2022**, 193, 111	1
420	Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?. **2022**, 14,	1
419	Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer.. **2022**, 22, 285	
418	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.. **2022**, 22, 222	0
417	A comprehensive analysis of immune landscape of Indian triple negative breast cancer.	
416	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. **2022**, 22, 40-50	
415	Long Noncoding RNA: Shining Stars in the Immune Microenvironment of Gastric Cancer.. **2022**, 12, 862337	1
414	Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer.. **2022**, 24, 624-635	0

| 413 | Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. **2022**, JCO2101536 | 2 |

| 412 | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.. **2022**, 14, | 0 |

| 411 | The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.. **2022**, 1 | 1 |

| 410 | Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.. **2022**, JCO2102010 | 0 |

| 409 | Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.. **2022**, 14, | |

| 408 | Gastric carcinoma with lymphoid stroma derived from hamartomatous inverted polyp with osteoclast-like giant cells: a case report. | 1 |

| 407 | Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer.. **2022**, | 1 |

| 406 | Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+ HER2 Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy. | 0 |

| 405 | WeakSTIL: weak whole-slide image level stromal tumor infiltrating lymphocyte scores are all you need. **2022**, | 0 |

| 404 | Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. **2022**, 106, 102392 | 4 |

| 403 | A deep learning-based computational prediction model for characterizing cellular biomarker distribution in tumor microenvironment. **2022**, | |

| 402 | In the use of artificial intelligence and hyperspectral imaging in digital pathology for breast cancer cell identification. **2022**, | |

| 401 | The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.. **2022**, 41, 127 | 4 |

| 400 | Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.. **2022**, 165, 157-168 | 1 |

| 399 | Magnetic resonance imaging of tumor-infiltrating lymphocytes by anti-CD3-conjugated iron oxide nanoparticles.. **2022**, | |

| 398 | PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells.. **2022**, 11, 2054305 | 2 |

| 397 | A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.. **2022**, 149, 110220 | 0 |

| 396 | DDTNet: A dense dual-task network for tumor-infiltrating lymphocyte detection and segmentation in histopathological images of breast cancer.. **2022**, 78, 102415 | 2 |

395	Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach.. **2022**, 19, 101380	0
394	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial..	0
393	The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer.. **2022**, 41, 101725	
392	Relationship between the changes of positivity rate of HER2 expression and the diameter of invasive lesions in early breast cancer and its clinical significance.. **2022**, 233, 153877	0
391	The relationship of tumor budding with GOLPH3 expression and histopathological prognostic parameters in colorectal adenocarcinoma.. **2022**, 58, 151933	
390	Multi-Class Cell Detection Using Spatial Context Representation. **2021**,	1
389	The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma.. **2021**, 13,	3
388	Assessment of breast cancer mesenchymal tumor infiltrating lymphocytes based on regional segmentation and nuclear segmentation classification. **2021**,	
387	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.. **2021**, 14, 206	2
386	The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer.. **2021**,	
385	Comprehensive Analysis of the Effects of Genetic Ancestry and Genetic Characteristics on the Clinical Evolution of Oral Squamous Cell Carcinoma.. **2021**, 9, 678464	
384	The Macroscopic and Microscopic Evaluation of Breast and Axillary Lymph Node Specimens Following Neoadjuvant Systemic Therapy for Breast Cancer. **2022**, 19-45	
383	Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy.. **2021**, 13,	0
382	The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.. **2021**, 23, 118	1
381	Evolution of synchronous bilateral breast cancers provide insights into interactions between host, tumor and immunity.	
380	Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers.. **2021**, 100, e28057	0
379	EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis.. **2022**, 30, 157-164	0
378	TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer.. **2021**, 11, 740427	0

377   Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.. **2021**,   1

376   Defining the area of mitoses counting in invasive breast cancer using whole slide image.. **2021**,   0

375   Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.. **2022**, 30, 246-256

374   Tumor-Infiltrating Lymphocytes Improve Magee Equation-Based Prediction of Pathologic Complete Response in HR-Positive/HER2-Negative Breast Cancer.. **2022**,   1

373   Clinicopathologic and Genomic Features in Triple-Negative Breast Cancer Between Special and No-Special Morphologic Pattern.. **2022**, 12, 830124   0

372   Immunotherapy in triple-negative breast cancer: A literature review and new advances.. **2022**, 13, 219-236   2

371   The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer.. **2022**, 13, 27   1

370   Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer.. **2022**,

369   Tumor immune microenvironment and response to neoadjuvant chemotherapy in hormone receptor/HER2+ early stage breast cancer. **2022**,   1

368   Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes.. **2022**, 14,   0

367   Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.. **2022**, 14,   1

366   DataSheet_1.pdf. **2021**,

365   Table_1.docx. **2021**,

364   table_1.docx. **2018**,

363   Data_Sheet_1.docx. **2018**,

362   Image_1.TIF. **2018**,

361   Image_2.TIF. **2018**,

360   Image_3.TIF. **2018**,

359   Image_4.TIF. **2018**,

358   Image_5.TIF. **2018**,

357   Image_6.TIF. **2018**,

356   Image_7.TIF. **2018**,

355   Table_1.XLSX. **2018**,

354   Table_2.XLSX. **2018**,

353   Image_1.TIF. **2019**,

352   Image_2.TIF. **2019**,

351   Image_3.TIF. **2019**,

350   Image_4.tif. **2019**,

349   Table_1.DOCX. **2019**,

348   Table_2.DOCX. **2019**,

347   Table_3.DOCX. **2019**,

346   Table_4.DOCX. **2019**,

345   Table_5.DOCX. **2019**,

344   Table_6.DOCX. **2019**,

343   Image_1.TIF. **2019**,

342   Image_2.TIF. **2019**,

341 Table_1.docx. **2021**,

340 Image_1.TIF. **2020**,

339 Image_2.TIF. **2020**,

338 Image_3.TIF. **2020**,

337 Image_4.TIF. **2020**,

336 Image_5.TIF. **2020**,

335 Image_6.TIF. **2020**,

334 Image_7.TIF. **2020**,

333 Image_8.TIF. **2020**,

332 Image_9.TIF. **2020**,

331 Table_1.DOCX. **2020**,

330 Table_2.DOCX. **2020**,

329 Table_3.docx. **2020**,

328 Table_1.DOCX. **2019**,

327 image_1.PDF. **2018**,

326 image_2.PDF. **2018**,

325 image_3.PDF. **2018**,

324 image_4.PDF. **2018**,

323   image_5.PDF. **2018**,

322   image_6.PDF. **2018**,

321   image_7.PDF. **2018**,

320   image_8.PDF. **2018**,

319   table_1.xlsx. **2018**,

318   Image_1.JPEG. **2019**,

317   Image_2.JPEG. **2019**,

316   Image_3.JPEG. **2019**,

315   Image_4.JPEG. **2019**,

314   Image_5.JPEG. **2019**,

313   Image_6.JPEG. **2019**,

312   Table_1.DOCX. **2019**,

311   Table_2.DOCX. **2019**,

310   Table_3.DOCX. **2019**,

309   Table_4.DOCX. **2019**,

308   Table_5.DOCX. **2019**,

307   Table_6.DOCX. **2019**,

306   Table_7.DOCX. **2019**,

305	Tumor infiltrating lymphocytes-based subtypes and genomic characteristics of EBV- associated lymphoepithelioma-like carcinoma.. **2022**,	
304	Subclassifying triple-negative breast cancers and its potential clinical utility.. **2022**, 1	0
303	Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial.. **2022**,	3
302	Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.. **2022**, 20, 136	1
301	Is there still a place for conventional histopathology in the age of molecular medicine? Laurß classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. **2021**, 36, 587-613	3
300	Nanomaterial Technology and Triple Negative Breast Cancer.. **2021**, 11, 828810	1
299	Tumor infiltrating lymphocytes in head and neck squamous cell carcinoma - Evaluation and clinical impact.. **2022**, 18, 49-54	1
298	Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy.. **2021**, 13, 12750-12762	
297	Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.. **2022**, 14,	0
296	Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients.. **2022**, 23,	0
295	Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. **2022**, 12,	0
294	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma.. **2022**, 13, 863796	
293	Development of an immune-related prognostic biomarker for triple-negative breast cancer.. **2022**, 54, 1212-1220	0
292	The Immune Microenvironment in Gastric Cancer: Prognostic Prediction.. **2022**, 12, 836389	0
291	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.. **2022**, 8, 56	1
290	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.. **2022**, 14,	2
289	Prognostic Impact of Tumor-infiltrating Lymphocytes and Neutrophils in Resected Non-small Cell Lung Carcinoma.. **2022**,	0
288	Expression and clinical prognostic value of CYB561 in breast cancer.. **2022**, 1	0

287	The prognostic value of stromal tumor-infiltrating lymphocytes in intrahepatic cholangiocarcinoma: a population-based study.. **2022**, 1-7	0
286	Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.. **2022**,	1
285	A Presurgical-Window Intervention Trial of Isothiocyanate-Rich Broccoli Sprout Extract in Patients with Breast Cancer.. **2022**, e2101094	1
284	Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer.. **2022**, 23, 197	0
283	Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy.. **2022**, 105833	1
282	Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer.. **2022**, 14,	1
281	Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2. **2022**, 10, 1061	0
280	Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.. **2022**, 22, 548	0
279	Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. **2022**, 14, 2467	0
278	Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression.. **2022**, 12, 8098	0
277	NuCLS: A scalable crowdsourcing approach and dataset for nucleus classification and segmentation in breast cancer.. **2022**, 11,	7
276	Immuno-oncological era of breast cancer: A progressive path to better treatment. 1-4	
275	A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. **2022**, 13,	2
274	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response. **2022**, 14, 2525	0
273	Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. **2022**, 8, e09474	
272	Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma.	2
271	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. **2022**, 8,	0
270	Inter-observer agreement of Tumor Infiltrating Lymphocytes in primary HER2-positive breast cancer and correlation between Tissue microarray and full tumor-sections..	

| 269 | Development and validation of a computed tomography‑based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer. | 0 |

| 268 | Protein profiling of breast carcinomas reveals expression of immune-suppressive factors and signatures relevant to patient outcome. | |

| 267 | Prognostic value of tumor-infiltrating CD163+macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment. **2022**, 22, | |

| 266 | Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. **2022**, 6, | 1 |

| 265 | Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. **2022**, 16, 117955549221099 | 2 |

| 264 | Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer. | |

| 263 | Response-based molecular subtyping‑emergence of the third generation of breast cancer subtypes. **2022**, 40, 592-594 | |

| 262 | GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. **2022**, 8, | 0 |

| 261 | A Pragmatic Machine Learning Approach to Quantify Tumor-Infiltrating Lymphocytes in Whole Slide Images. **2022**, 14, 2974 | 0 |

| 260 | SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. **2022**, 14, 3042 | |

| 259 | Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting. | 1 |

| 258 | No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC. **2022**, 14, 3080 | |

| 257 | Clinical and morphological features of non-small cell lung cancer in patients with different types of histological changes to the bronchial epithelium. **2022**, | |

| 256 | Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. **2022**, 12, 941 | 0 |

| 255 | DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. **2022**, 24, | 3 |

| 254 | The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. **2022**, 11, 1944 | |

| 253 | Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. 28, | 1 |

| 252 | Tumor Infiltrating Lymphocytes in Breast Cancer: Implementation of a New Histopathological Biomarker. **2022**, 207-243 | 1 |

233	Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.	0
232	Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. **2022**, 8,	0
231	Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms. **2022**, 9,	
230	Timing evolution of lobular breast cancer through phylogenetic analysis. **2022**, 82, 104169	
229	Tumor-infiltrating lymphocytes predict survival in ⫘pT2 urothelial bladder cancer. **2022**, 237, 154037	0
228	Diversification and shared features of tumor-binding antibody repertoires in tumor, sentinel lymph node and blood of three patients with breast cancer. **2022**, 11,	
227	HER2-low breast cancer shows a lower immune response compared to HER2-negative cases. **2022**, 12,	2
226	Immunologic determinants of mammary tumors: PD-L1 and TILS. **2022**, 35, S60-S66	
225	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. 12,	
224	Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles. **2022**, 11, 2286	1
223	Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. **2022**, 14, 3876	2
222	Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer. 13,	0
221	PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.	
220	The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively.	
219	Variable prognostic value of stromal tumor-infiltrating lymphocytes and CD3+T cells in schistosomal and non-schistosomal colorectal cancer.	
218	Connected-SegNets: A Deep Learning Model for Breast Tumor Segmentation from X-ray Images. **2022**, 14, 4030	1
217	Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. **2022**, 28, 1646-1655	2
216	Early triple negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expression.	

197 Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. **2022**, 25, 101511

196 Relationship between Aldehyde Dehydrogenase, PD-L1 and Tumor-Infiltrating Lymphocytes with Pathologic Response and Survival in Breast Cancer. **2022**, 14, 4418 | 0

195 STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. | 0

194 CD47 expression and tumor-associated immune cells in breast cancer and their correlation with molecular subtypes and prognostic factors. **2022**, 238, 154107 | 0

193 Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. **2022**, 14, 175883592211132 | 0

192 Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?. **2022**, | 0

191 The tumor microenvironment. **2022**, 31-58 | 2

190 Research on the Correlation between TILs and Neoadjuvant Efficacy in Breast Cancer. **2022**, 12, 7353-7359 | 0

189 Role of Membrane Estrogen Receptor (GPER1) on the Function of Immune Cells and Its Consequences on Breast Cancer Pathophysiology. **2022**, | 0

188 The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy. **2022**, 2022, 1-10 | 0

187 Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer. **2022**, 8, e10482 | 0

186 Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy. | 0

185 Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas. **2022**, 22, | 1

184 Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy Resistant Early Breast Cancers. OF1-OF15 | 0

183 Recent advances in photothermal therapy-based multifunctional nanoplatforms for breast cancer. 10, | 1

182 CD133 is an independent predictive and prognostic marker in metastatic breast cancer. **2022**, 1-9 | 0

181 High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer. **2022**, 19, 246-256 | 0

180 Immunohistochemical Markers and TILs Evaluation for Endometrial Carcinoma. **2022**, 11, 5678 | 0

179	Prognostic Relevance of Nuclear Receptors in Relation to Peritumoral Inflammation and Tumor Infiltration by Lymphocytes in Breast Cancer. **2022**, 14, 4561	0
178	INSC Is a Prognosis-Associated Biomarker Involved in Tumor Immune Infiltration in Colon Adenocarcinoma. **2022**, 2022, 1-9	0
177	Spatially variant immune infiltration scoring in human cancer tissues. **2022**, 6,	0
176	Predicting the risk of axillary lymph node metastasis in early breast cancer patients based on ultrasonographic-clinicopathologic features and the use of nomograms: a prospective single-center observational study.	0
175	Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer. Publish Ahead of Print,	0
174	Biomarkers and immunotherapy: where are we?. **2022**, 34, 579-586	1
173	Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer. 12,	0
172	Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome. **2022**, 14, 4542	0
171	Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. **2022**, 14, 4279	0
170	Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis. **2022**,	0
169	Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer.	1
168	The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer. **2022**,	0
167	Features of lymph node metastasis depending on intratumoral heterogeneity of non-small cell lung cancer in patients with different morphological changes in the bronchial epithelium. **2022**, 21, 69-81	0
166	Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2Negative Postmenopausal Breast Cancer Patients. **2022**, 14, 4844	0
165	Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer. **2022**, 14, 4971	0
164	Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy. **2022**, 14, 5008	1
163	Metastatic pancreatic neuroendocrine tumors manifest elevated T cell infiltration.	0
162	Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. **2022**, 14, 4829	2

161	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. **2022**, 10, e005119	1
160	Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. **2022**, 20,	3
159	Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer. **2022**, 23, 13235	0
158	Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. **2022**, 12, 2527	0
157	High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. **2022**, 24,	1
156	Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.	1
155	SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival. 13,	0
154	PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.	0
153	Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer:A multicenter study. **2022**, 66, 183-190	0
152	Application of Artificial Intelligence in Pathology: Trends and Challenges. **2022**, 12, 2794	1
151	Immune Cell Density Evaluation Improves the Prognostic Values of Staging and p16 in Oropharyngeal Cancer. **2022**, 14, 5560	0
150	Integrative prognostic analysis of tumorⅢnfiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.	0
149	Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies.	0
148	Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nursesⅢealth study. **2022**, 24,	0
147	CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. **2022**, 40, 1341-1357.e13	0
146	Induction of pulmonary HLA-G expression by SARS-CoV-2 infection. **2022**, 79,	0
145	Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer. **2022**,	0
144	AMPK activator AICAR in combination with anti-mouse IL10 mAb restores the functionality of intra-tumoral Tfh cells in the 4T1 mouse model. **2022**, 382, 104639	1

143	Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.	0
142	Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.	0
141	An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy.	0
140	Heterogalactan WPEP-N-b from Pleurotus eryngii enhances immunity in immunocompromised mice. **2022**,	0
139	Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. **2022**, 14, 5635	0
138	Less Common Triple-Negative Breast Cancers. **2022**, 463-573	0
137	Breast Cancer Pathology in the Era of Genomics. **2023**, 37, 33-50	0
136	Triple-Negative/Basal-Like Breast Carcinomas. **2022**, 445-462	0
135	Neo-peripheral adaptive immune score predicts neoadjuvant chemotherapy for locally advanced breast cancer.	0
134	One Step Nucleic Acid Amplification (OSNA) Lysate Samples Are Suitable to Establish a Transcriptional Metastatic Signature in Patients with Early Stage Hormone Receptors-Positive Breast Cancer. **2022**, 14, 5855	0
133	Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis. 12,	0
132	NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer. **2022**, 2022, 1-14	0
131	MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance and Immunosuppression in Triple-Negative Breast Cancer.	0
130	Survival outcomes, digital TILs and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial.	0
129	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. 13,	0
128	Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer. **2022**, 23, 14937	0
127	Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients. **2022**, 17,	0
126	Analysis of the significance of DNASE1L3 in immune infiltration of colon adenocarcinoma.	0

125	Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer. **2022**, 8,	0
124	Quantitative Assessment of Tumor-Infiltrating Lymphocytes Using Machine Learning Predicts Survival in Muscle-Invasive Bladder Cancer. **2022**, 11, 7081	1
123	Is it possible to identify subpopulations of triple negative breast cancer?. **2022**, 13, 352-360	0
122	The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study. **2022**, 11, 1421	0
121	Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer. 13,	0
120	The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. OF1-OF18	1
119	Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors.	1
118	Spatial biology of cancer evolution.	4
117	Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma. **2022**, 154289	0
116	Update on triple-negative breast cancers Ihighlighting subtyping update and treatment implication. **2023**, 82, 17-35	2
115	Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.	0
114	Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. **2022**, 7, 100636	0
113	Association of longer telomere length in cancer cells and cancer-associated fibroblasts with worth prognosis.	0
112	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. **2022**, 14, 6034	1
111	Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer. **2023**, 82, 170-188	1
110	Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.	0
109	Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand. 12,	0
108	The chemotherapeutic activity of areca nut extract increased stromal tumor-infiltrating lymphocytes in 4-nutriquinoline-1-oxide-tumor-induced Sprague-Dawley rats. 11, 1571	0

107	Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. **2022**, 10, e005543	0
106	Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer. 13,	0
105	Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients. **2022**, 27,	0
104	Assessment of cellular and humoral immunity in sentinel lymph node in breast cancer. **2022**, 21, 13-18	0
103	Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.	0
102	Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR Trial. OF1-OF10	0
101	Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer.	0
100	Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology. 12,	0
99	Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response.	0
98	CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis.	0
97	The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. **2023**, 16,	0
96	Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies. **2023**, 11, 238	0
95	Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance. **2023**, e13048	0
94	Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. **2023**, 9,	0
93	Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy. 28,	0
92	Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. **2023**, 24, 818	0
91	p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance. **2023**, 100100	0
90	Theranostics for Triple-Negative Breast Cancer. **2023**, 13, 272	1

| 89 | Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar. **2023**, 18, | 0 |

| 88 | Standardized pathology screening of mature Tertiary Lymphoid Structures in cancers. **2023**, 100063 | 0 |

| 87 | Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathologic parameters. | 1 |

| 86 | Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression. **2023**, 100056 | 0 |

| 85 | Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. 12, | 0 |

| 84 | Differential Regulation of Innate Lymphoid Cells in Human and Murine Oral Squamous Cell Carcinoma. **2023**, 24, 1627 | 0 |

| 83 | Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). | 0 |

| 82 | Cancer Microenvironment Defines Tumor-Infiltrating Lymphocyte Density and Tertiary Lymphoid Structure Formation in Laryngeal Cancer. | 2 |

| 81 | A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. **2022**, 12, | 1 |

| 80 | A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. **2022**, 8, | 0 |

| 79 | Sarcopenia using pectoralis muscle area and lymphocyte-to-monocyte ratio (LMR) are independent prognostic factors in patients for nonmetastatic breast cancer. **2022**, 101, e32229 | 0 |

| 78 | Systemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part I. Tumor-Promoting Inflammation. Serum Inflammatory Markers. **2022**, 77, 345-353 | 0 |

| 77 | Relationship between Tumor Infiltrating Immune Cells and Tumor Metastasis and Its Prognostic Value in Cancer. **2023**, 12, 64 | 0 |

| 76 | Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial. **2023**, | 0 |

| 75 | Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role?. **2023**, | 0 |

| 74 | Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens. jcp-2022-208637 | 0 |

| 73 | Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer. **2023**, 29, 135-146 | 0 |

| 72 | Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. **2023**, 25, | 0 |

71	Artificial Intelligence for Cancer Detection–A Bibliometric Analysis and Avenues for Future Research. **2023**, 30, 1626-1647	o
70	Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances. **2023**, 14, 376	o
69	Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. **2023**, 12, 953	o
68	Systemic immune mediators reflect tumor-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer.	o
67	Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images. **2023**, 7,	o
66	Deep Learning with Transformer or Convolutional Neural Network in the Assessment of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Based on US Images: A Dual-Center Retrospective Study. **2023**, 15, 838	o
65	Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. **2023**, 11, e005809	o
64	Breaking the Photostability and pH Limitation of Halo-Fluoresceins through Chitosan Conjugation. 2210956	o
63	The association between CD3+ and CD8+tumor-infiltrating lymphocytes (TILs) and prognosis in patients with pancreatic adenocarcinoma. **2023**, 35, 100699	o
62	Higher Levels of Tumour-Infiltrating Lymphocytes (TILs) are Associated with a Better Prognosis, While CDK5 Plays a Different Role Between Nonmetastatic and Metastatic Colonic Carcinoma. **2023**, 30, 107327482311693	o
61	Role of stromal PD-L1 expression in colorectal liver metastasis.	o
60	Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. **2023**, 36, 100125	o
59	Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response. **2023**, 161, 114546	o
58	Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. **2023**, 69, 330-341	o
57	Clinical significance of overall assessment of tumor-infiltrating lymphocytes in oropharyngeal cancer: A meta-analysis. **2023**, 243, 154342	o
56	Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. **2023**, 15, 767	o
55	Artificial intelligence-based digital scores of stromal tumour-infiltrating lymphocytes and tumour-associated stroma predict disease-specific survival in triple-negative breast cancer. **2023**, 260, 32-42	o
54	S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment. **2023**, 9, e13294	o

| 53 | Comparison of the prognostic value of stromal tumor-infiltrating lymphocytes and CD3 + T cells between schistosomal and non-schistosomal colorectal cancer. **2023**, 21, | 0 |

| 52 | Distinct role of tumor-infiltrating lymphocytes between synchronous and metachronous colorectal cancer. **2023**, 408, | 0 |

| 51 | Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. **2023**, 24, 2969 | 0 |

| 50 | Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy. **2023**, 47, 1238-1246 | 0 |

| 49 | Prognostic role of immune environment in luminal B early breast cancer. | 0 |

| 48 | Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial. **2023**, 183, 152-161 | 0 |

| 47 | Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. **2023**, 29, 450-457 | 2 |

| 46 | Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients. **2023**, 13, | 0 |

| 45 | Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. **2023**, 15, 1164 | 0 |

| 44 | Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer. 14, | 0 |

| 43 | ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations. **2023**, 15, 1199 | 0 |

| 42 | Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging. 34, | 0 |

| 41 | Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. 13, | 0 |

| 40 | Prognostic significance of tumour infiltrating lymphocytes in different molecular subtypes of invasive breast carcinoma. **2020**, 15, 89-95 | 0 |

| 39 | Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy. | 0 |

| 38 | Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer. **2023**, 15, 175883592311576 | 0 |

| 37 | Tumor Microenvironment and Immune Response in Lip Cancer. **2023**, 15, 1478 | 0 |

| 36 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. **2023**, 24, 273-285 | 0 |

17	Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial. **2023**, 15, 2030	0
16	Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics.	0
15	Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy.	0
14	Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial.	0
13	PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.	1
12	Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer. **2023**, 30, 4094-4109	0
11	Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer. **2023**, 59, 728	0
10	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194	0
9	Computational pathology to improve biomarker testing in breast cancer: how close are we?. Publish Ahead of Print,	0
8	Challenges in Computational Pathology of Biomarker-Driven Predictive and Prognostic Immunotherapy. **2023**, 1-19	0
7	Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. **2023**, 14,	0
6	The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer. **2023**, 9,	0
5	The Prognostic Role of the Immune Microenvironment in Sinonasal Intestinal-Type Adenocarcinoma: A Computer-Assisted Image Analysis of CD3+ and CD8+ Tumor-Infiltrating Lymphocytes. **2023**, 13, 726	0
4	Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. **2023**,	0
3	Evaluation of the RDW Index (Red Cell Distribution Width) in Women with Breast Cancer Treated with Doxorubicin in a One-Year Follow-Up Study. **2023**, 13, 1552	0
2	The prognostic significance of non-lymphoid immune cells of the tumor microenvironment, including neutrophils, eosinophils, and mast cells in breast carcinomas. **2023**, 65, 152151	0
1	Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. **2023**, 9,	0